Loretta J. Nastoupil, M.D.

Peer-Reviewed Articles

1. Gordon MJ, Smith MR, Nastoupil LJ. Follicular lymphoma: The long and winding road leading to your cure?. Blood Rev 57:100992, 2023. e-Pub 2022. PMID: 35908982.
2. Lillemoe HA, Miranda RN, Nastoupil LJ, Clemens MW, Hunt KK. Clinical Manifestations and Surgical Management of Breast Implant-Associated Anaplastic Large Cell Lymphoma: Beyond the NCCN Guidelines. Ann Surg Oncol 29(9):5722-5729, 2022. e-Pub 2022. PMID: 35597841.
3. Cherng HJ, Sun R, Sugg B, Irwin R, Yang H, Le CC, Deng Q, Fayad L, Fowler NH, Parmar S, Steiner R, Hagemeister F, Nair R, Lee HJ, Rodriguez M, Samaniego F, Iyer SP, Flowers CR, Wang L, Nastoupil LJ, Neelapu SS, Ahmed S, Strati P, Green MR, Westin J. Risk assessment with low pass whole genome sequencing of cell free DNA before CD19 CAR T-cells for large B-cell lymphoma. Blood 140(5):504-515, 2022. e-Pub 2022. PMID: 35512184.
4. Budde LE, Sehn LH, Matasar M, Schuster SJ, Assouline S, Giri P, Kuruvilla J, Canales M, Dietrich S, Fay K, Ku M, Nastoupil L, Cheah CY, Wei MC, Yin S, Li CC, Huang H, Kwan A, Penuel E, Bartlett NL. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol 23(8):1055-1065, 2022. e-Pub 2022. PMID: 35803286.
5. Steiner RE, Banchs J, Koutroumpakis E, Becnel M, Gutierrez C, Strati P, Pinnix CC, Feng L, Rondon G, Claussen C, Palaskas N, Karimzad K, Ahmed S, Neelapu SS, Shpall E, Wang M, Vega F, Westin J, Nastoupil LJ, Deswal A. Cardiovascular events in patients treated with chimeric antigen receptor t-cell therapy for aggressive B-cell lymphoma. Haematologica 107(7):1555-1566, 2022. e-Pub 2022. PMID: 34758610.
6. Riedell PA, Hwang WT, Nastoupil LJ, Pennisi M, McGuirk JP, Maziarz RT, Bachanova V, Oluwole OO, Brower J, Flores OA, Ahmed N, Schachter L, Bharucha K, Dholaria BR, Schuster SJ, Perales MA, Bishop MR, Porter DL. Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B-cell Lymphomas. Transplant Cell Ther. e-Pub 2022. PMID: 35850429.
7. Chihara D, Huang EP, Finnigan SR, Cordes LM, Skorupan N, Fukuda Y, Rubinstein LV, Ivy SP, Doroshow JH, Nastoupil LJ, Flowers CR, Takebe N. Trends in Grade 5 Toxicity and Response in Phase I Trials in Hematologic Malignancy: 20-Year Experience From the Cancer Therapy Evaluation Program at the National Cancer Institute. J Clin Oncol 40(17):JCO2102190, 2022. e-Pub 2022. PMID: 35263120.
8. Marques-Piubelli ML, Parra ER, Feng L, Soto LS, Gallardo M, Gouni S, Samaniego F, Noorani M, Hagemeister FB, Westin JR, Lee HJ, Rodriguez MA, Neelapu SS, Gunther JR, Fowler NH, Flowers CR, Wistuba II, Nastoupil LJ, Vega F, Strati P. SIRPα+ macrophages are increased in patients with FL who progress or relapse after frontline lenalidomide and rituximab. Blood Adv 6(11):3286-3293, 2022. e-Pub 2022. PMID: 35359004.
9. Al Zaki A, Feng L, Watson G, Ahmed SA, Mistry H, Nastoupil LJ, Hawkins M, Nair R, Iyer SP, Lee HJ, Steiner RE, Flowers CR, Shpall EJ, Kebriaei P, Neelapu SS, Westin JR, Strati P. Day 30 SUVmax Predicts Progression in Lymphoma Patients Achieving PR/SD After CAR T-cell Therapy. Blood Adv 6(9):2867-2871, 2022. e-Pub 2022. PMID: 35015825.
10. Amini L, Silbert SK, Maude SL, Nastoupil LJ, Ramos CA, Brentjens RJ, Sauter CS, Shah NN, Abou-El-Enein M. Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion. Nat Rev Clin Oncol 19(5):342-355, 2022. e-Pub 2022. PMID: 35318469.
11. Thanarajasingam G, Minasian LM, Bhatnagar V, Cavalli F, De Claro RA, Dueck AC, El-Galaly TC, Everest N, Geissler J, Gisselbrecht C, Gormley N, Gribben J, Horowitz M, Ivy SP, Jacobson CA, Keating A, Kluetz PG, Kwong YL, Little RF, Matasar MJ, Mateos MV, McCullough K, Miller RS, Mohty M, Moreau P, Morton LM, Nagai S, Nair A, Nastoupil L, Robertson K, Sidana S, Smedby KE, Sonneveld P, Tzogani K, van Leeuwen FE, Velikova G, Villa D, Wingard JR, Seymour JF, Habermann TM. Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies. Lancet Haematol 9(5):e374-e384, 2022. PMID: 35483398.
12. Saini NY, Swoboda DM, Greenbaum U, Ma J, Patel RD, Devashish K, Das K, Tanner MR, Strati P, Nair R, Fayad L, Ahmed S, Lee HJ, Iyer SP, Steiner R, Jain N, Nastoupil L, Loghavi S, Tang G, Bassett RL, Jain P, Wang M, Westin JR, Green MR, Sallman DA, Padron E, Davila ML, Locke FL, Champlin RE, Garcia-Manero G, Shpall EJ, Kebriaei P, Flowers CR, Jain MD, Wang F, Futreal AP, Gillis N, Neelapu SS, Takahashi K. Clonal hematopoiesis is associated with increased risk of severe neurotoxicity in axicabtagene ciloleucel therapy of large B-cell lymphoma. Blood Cancer Discov. e-Pub 2022. PMID: 35533245.
13. Lillemoe HA, Miranda RN, Nastoupil LJ, Clemens MW, Hunt KK. ASO Visual Abstract: Clinical Manifestations and Surgical Management of Breast Implant-Associated Anaplastic Large Cell Lymphoma-Beyond the NCCN Guidelines. Ann Surg Oncol. e-Pub 2022. PMID: 35606472.
14. Casulo C, Larson MC, Lunde JJ, Habermann TM, Lossos IS, Wang Y, Nastoupil LJ, Strouse C, Chihara D, Martin P, Cohen JB, Kahl BS, Burack WR, Koff JL, Mun Y, Masaquel A, Wu M, Wei MC, Shewade A, Li J, Cerhan J, Flowers CR, Link BK, Maurer MJ. Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study. Lancet Haematol 9(4):e289-e300, 2022. PMID: 35358443.
15. Ma MCJ, Tadros S, Bouska A, Heavican T, Yang H, Deng Q, Moore D, Akhter A, Hartert K, Jain N, Showell J, Ghosh S, Street L, Davidson M, Carey C, Tobin J, Perumal D, Vose JM, Lunning MA, Sohani AR, Chen BJ, Buckley S, Nastoupil LJ, Davis RE, Westin JR, Fowler NH, Parekh S, Gandhi M, Neelapu S, Stewart D, Bhalla K, Iqbal J, Greiner T, Rodig SJ, Mansoor A, Green MR. Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma. Haematologica 107(3):690-701, 2022. e-Pub 2022. PMID: 33792219.
16. Wang ML, Jain P, Zhao S, Lee HJ, Nastoupil L, Fayad L, Ok CY, Kanagal-Shamanna R, Hill HA, Yao Y, Hagemeister FB, Westin JR, Fowler N, Samaniego F, Steiner R, Nair R, Iyer SP, Navsaria L, Badillo M, Mantle Cell Research Group, Feng L, Xuelin H, Nogueras Gonzalez GM, Xu G, Wagner-Bartak N, Thirumurthi S, Santos D, Tang G, Lin P, Wang SA, Jorgensen J, Yin CC, Li S, Patel KP, Vega F, Medeiros LJ, Flowers CR, Wang L. Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (=65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial. Lancet Oncol 23(3):406-415, 2022. e-Pub 2022. PMID: 35074072.
17. Budde LE, Assouline S, Sehn LH, Schuster SJ, Yoon SS, Yoon DH, Matasar MJ, Bosch F, Kim WS, Nastoupil LJ, Flinn IW, Shadman M, Diefenbach C, O'Hear C, Huang H, Kwan A, Li CC, Piccione EC, Wei MC, Yin S, Bartlett NL. Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study. J Clin Oncol 40(5):JCO2100931, 2022. e-Pub 2021. PMID: 34914545.
18. Nastoupil LJ, Chin CK, Westin JR, Fowler NH, Samaniego F, Cheng X, Ma MCJ, Wang Z, Chu F, Dsouza L, Obi C, Mims J, Feng L, Zhou S, Green M, Davis RE, Neelapu SS. Safety and activity of pembrolizumab in combination with rituximab in relapsed or refractory follicular lymphoma. Blood Adv 6(4):1143-1151, 2022. e-Pub 2022. PMID: 35015819.
19. Cherng HJ, Chuang HH, Steiner R, Fayad L, Strati P, Nair R, Hagemeister F, Nastoupil LJ, Lee HJ, Neelapu SS, Flowers CR, Samaniego F, Rodriguez M, Macapinlac HA, Feng L, Westin J. A prospective study on early PET/CT scans during the first cycle of salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma. Leuk Lymphoma 63(1):1-10, 2022. e-Pub 2021. PMID: 34435552.
20. Khouri IF, Milton DR, Gulbis AM, Jabbour EJ, Nastoupil L, Ledesma C, Anderlini P, Bashir Q, Daher M, Im JS, Iyer SP, Marin D, Mehta RS, Olson AL, Popat UR, Qazilbash M, Saini N, Samaniego F, Rondon G, Medeiros LJ, Champlin RE. 9-year follow-up of patients with relapsed follicular lymphoma after nonmyeloablative allogeneic stem cell transplant and autologous transplant. Clin Cancer Res 27(21):5847-5856, 2021. e-Pub 2021. PMID: 34380640.
21. Santomasso BD, Nastoupil LJ, Adkins S, Lacchetti C, Schneider BJ, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I, Davies MJ, Ernstoff MS, Fecher L, Funchain P, Jaiyesimi I, Mammen JS, Naidoo J, Naing A, Phillips T, Porter LD, Reichner CA, Seigel C, Song JM, Spira A, Suarez-Almazor M, Swami U, Thompson JA, Vikas P, Wang Y, Weber JS, Bollin K, Ghosh M. Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline. J Clin Oncol:JCO2101992. e-Pub 2021. PMID: 34724386.
22. Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I, Davies MJ, Ernstoff MS, Fecher L, Ghosh M, Jaiyesimi I, Mammen JS, Naing A, Nastoupil LJ, Phillips T, Porter LD, Reichner CA, Seigel C, Song JM, Spira A, Suarez-Almazor M, Swami U, Thompson JA, Vikas P, Wang Y, Weber JS, Funchain P, Bollin K. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol:JCO2101440. e-Pub 2021. PMID: 34724392.
23. Nastoupil LJ. The evolving use of CAR T-cell therapy in follicular lymphoma. Clin Adv Hematol Oncol 19(11):684-686, 2021. PMID: 34807012.
24. Strati P, Varma A, Adkins S, Nastoupil LJ, Westin J, Hagemeister FB, Fowler NH, Lee HJ, Fayad LE, Samaniego F, Ahmed S, Chen Y, Horowitz S, Arafat S, Johncy S, Kebriaei P, Mulanovich VE, Ariza Heredia E, Neelapu SS. Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma. Haematologica 106(10):2667-2672, 2021. e-Pub 2021. PMID: 32732355.
25. Al Feghali KA, Fang P, Gule-Monroe M, Milgrom S, Khoury JD, Gunther JR, Sheu T, Nair R, Ahmed S, Steiner R, Strati P, Shpall EJ, Nieto YL, Hosing C, Nastoupil LJ, Westin JR, Neelapu SS, Fowler N, Flowers C, Pinnix CC, Dabaja BS. Prognostic value of disease distribution in secondary central nervous system diffuse large B cell lymphoma treated with radiation therapy. Leuk Lymphoma 62(10):1-8, 2021. e-Pub 2021. PMID: 33942701.
26. Crombie JL, Nastoupil LJ, Redd R, Tang K, Shouse G, Herrera AF, Chow VA, Shadman M, Castaneda Puglianini O, Saucier A, Jacobson CA, Armand P, Simmons G. Real-world outcomes of axicabtagene ciloleucel in adult patients with primary mediastinal B-cell lymphoma. Blood Adv 5(18):3563-3567, 2021. PMID: 34474474.
27. Nastoupil LJ, Neelapu SS, Davis RE, Samaniego F, Fowler NH, Westin J, Lee HJ, Wang M, Hagemeister F, Cecil ARL, Dow J, Haque K, Silva FA, Whale A, Lensun L, Bone EA, McElwaine-Johnn H, Beer PA. Preclinical and phase I studies of KA2237, a selective and potent inhibitor of PI3K β/δ in relapsed refractory B cell lymphoma. Leuk Lymphoma:1-11. e-Pub 2021. PMID: 34365878.
28. Courville J, Nastoupil L, Kaila N, Kelton J, Zhang J, Alcasid A, Nava-Parada P. Factors Influencing Infusion-Related Reactions Following Dosing of Reference Rituximab and PF-05280586, a Rituximab Biosimilar. BioDrugs 35(4):459-468, 2021. e-Pub 2021. PMID: 34152584.
29. Greenbaum U, Strati P, Saliba RM, Torres J, Rondon G, Nieto Y, Hosing C, Srour SA, Westin J, Fayad LE, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Flowers CR, Tummala S, Ramdial JL, Yalniz FF, Hawkins M, Rezvani K, Champlin RE, Shpall EJ, Neelapu SS, Kebriaei P, Ahmed S. CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity. Blood Adv 5(14):2799-2806, 2021. PMID: 34264268.
30. Augustyn A, Medeiros LJ, Ludmir EB, Gunther J, Fang P, Li S, Ok CY, Bankston ME, Verma V, Pasalic D, Ahmed S, Nastoupil LJ, Westin JR, Strati P, Neelapu SS, Nair R, Steiner RE, Iyer SP, Rodriguez A, Fayad LE, Flowers CR, Dabaja BS, Pinnix CC. The impact of cell-of-origin, MYC/Bcl-2 dual expression and MYC rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapy. Leuk Lymphoma 62(6):1-12, 2021. e-Pub 2021. PMID: 33480830.
31. Strati P, Ahmed S, Furqan F, Fayad LE, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Horowitz SB, Feng L, Sun R, Claussen CM, Hawkins MC, Johnson NA, Singh P, Mistry H, Johncy S, Adkins S, Kebriaei P, Shpall EJ, Green MR, Flowers CR, Westin J, Neelapu SS. Prognostic Impact of Corticosteroids on Efficacy of Chimeric Antigen Receptor T-cell Therapy in Large B-cell Lymphoma. Blood 137(23):3272-3276, 2021. e-Pub 2021. PMID: 33534891.
32. Qiu L, Weitzman SP, Nastoupil LJ, Williams MD, Medeiros LJ, Vega F. Disseminated ALK-positive histiocytosis with KIF5B-ALK fusion in an adult. Leuk Lymphoma 62(5):1-7, 2021. e-Pub 2020. PMID: 33353436.
33. Jain P, Kanagal-Shamanna R, Zhang S, Ok CY, Navsaria L, Nastoupil L, Lee HJ, Tang G, Yin CC, Badillo M, Nair R, Li S, Patel KM, Flowers C, Vega F, Wang L, Wang ML. Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib. Am J Hematol 96(5):E137-E140, 2021. e-Pub 2021. PMID: 33491779.
34. Munoz J, Follows GA, Nastoupil LJ. Copanlisib for the Treatment of Malignant Lymphoma: Clinical Experience and Future Perspectives. Target Oncol 16(3):295-308, 2021. e-Pub 2021. PMID: 33687623.
35. Joseph J, Ma J, Hennawy F, Abdulrazzaq MN, Saini N, Patel RD, Hosing CM, Alousi AM, Anderlini P, Popat UR, Qazilbash MH, Shpall EJ, Srour S, Kebriaei P, Bashir Q, Nastoupil LJ, Westin JR, Rondon G, Champlin RE, Andersson BS, Nieto Y, Muzzafar T, Ahmed S. Impact of Cell of Origin Classification on Survival Outcomes after Autologous Transplantation in Relapsed/Refractory Diffuse Large B Cell Lymphoma. Transplant Cell Ther 27(5):404.e1-404.e5, 2021. e-Pub 2021. PMID: 33965178.
36. Spiegel JY, Dahiya S, Jain MD, Tamaresis J, Nastoupil LJ, Jacobs MT, Ghobadi A, Lin Y, Lunning M, Lekakis L, Reagan P, Oluwole O, McGuirk J, Deol A, Goy A, Vu K, Andreadis C, Munoz J, Bennani NN, Vose JM, Dorritie KA, Neelapu SS, Locke FL, Rapoport AP, Hill BT, Miklos DB. Outcomes of Patients with Large B-cell Lymphoma Progressing after Axicabtagene Ciloleucel. Blood 137(13):1832-1835, 2021. e-Pub 2020. PMID: 33156925.
37. Fang P, Gunther JR, Pinnix CC, Dong W, Strati P, Nastoupil LJ, Steiner RE, Ahmed S, Damron EP, Fowler N, Nair R, Westin JR, Neelapu S, Ha CS, Dabaja BS. A Prospective Trial of Radiation Therapy Efficacy and Toxicity for Localized Mucosa-associated Lymphoid Tissue (MALT) Lymphoma. Int J Radiat Oncol Biol Phys 109(5):1414-1420, 2021. e-Pub 2020. PMID: 33309978.
38. Nastoupil LJ. When to Use Targeted Therapy for the Treatment of Follicular Lymphoma. Curr Hematol Malig Rep. e-Pub 2021. PMID: 33797691.
39. Lewis KL, Chin CK, Manos K, Casey J, Hamad N, Crawford J, Ho SJ, Issa S, Grigg A, Wood P, Gandhi MK, Do B, Nastoupil L, Hawkes EA, Cheah CY. Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience. Br J Haematol 192(6):1049-1053, 2021. e-Pub 2020. PMID: 32677095.
40. Strati P, Jain P, Johnson RJ, Forbes S, Feng L, Samaniego F, Rodriguez MA, Fayad LE, Hagemeister F, Westin J, Wang M, Neelapu SS, Nastoupil LJ, Fowler NH. Long Term Follow-Up of Lenalidomide and Rituximab as Initial Treatment of Follicular Lymphoma. Blood 137(8):1124-1129, 2021. e-Pub 2020. PMID: 32932518.
41. Samaniego F, McLaughlin P, Neelapu SS, Feng L, Fanale M, Nastoupil L, Rodriguez MA, Pro B, Taylor E, Hagemeister FB, Fowler N. Initial report of a phase II study with R-FND followed by ibritumomab tiuxetan radioimmunotherapy and rituximab maintenance in patients with untreated high-risk follicular lymphoma. Leuk Lymphoma 62(1):1-10, 2021. e-Pub 2020. PMID: 32924687.
42. Jain P, Nastoupil L, Westin J, Lee HJ, Navsaria L, Steiner RE, Ahmed S, Moghrabi O, Oriabure O, Chen W, Badillo M, Flowers CR, Wang ML. Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy. Br J Haematol 192(2):e38-e42, 2021. e-Pub 2020. PMID: 33152104.
43. Monga N, Garside J, Gurung B, Quigley J, O'Donovan P, Tapprich C, Nastoupil L, Thieblemont C, Loefgren C. Cost-Effectiveness Analyses, Costs and Resource Use, and Health-Related Quality of Life in Patients with Follicular or Marginal Zone Lymphoma: Systematic Reviews. Pharmacoecon Open 4(4):575-591, 2020. e-Pub 2020. PMID: 32200522.
44. Chin CK, Rodriguez MA, Qing Y, Feng L, Samaniego F, Jain P, Noorani M, Fowler NH, Fayad LE, Westin JR, Neelapu SS, Hagemeister FB, Flowers CR, Nastoupil LJ. Impact of maintenance rituximab in patients with de novo transformed indolent B cell lymphoma. Leuk Lymphoma 61(12):1-5, 2020. e-Pub 2020. PMID: 32628087.
45. Furqan F, Watson G, Samaniego F, Fayad LE, Rashmi Kanagal-Shamanna , Morrison MW, Thompson PA, Steiner RE, Chi L, Dabaja B, Pinnix CC, Neelapu SS, Nastoupil LJ, Strati P. Ibrutinib-based therapy for the treatment of marginal zone lymphoma with central nervous system involvement. Leuk Lymphoma 61(12):1-5, 2020. e-Pub 2020. PMID: 32650677.
46. Deng Q, Han G, Puebla-Osorio N, Ma MCJ, Strati P, Chasen B, Dai E, Dang M, Jain N, Yang H, Wang Y, Zhang S, Wang R, Chen R, Showell J, Ghosh S, Patchva S, Zhang Q, Sun R, Hagemeister F, Fayad L, Samaniego F, Lee HC, Nastoupil LJ, Fowler N, Eric Davis R, Westin J, Neelapu SS, Wang L, Green MR. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat Med. e-Pub 2020. PMID: 33020644.
47. Pinnix CC, Gunther JR, Fang P, Bankston ME, Milgrom SA, Boyce D, Lee HJ, Nair R, Steiner R, Strati P, Ahmed S, Iyer SP, Westin J, Parmar S, Rodriguez MA, Nastoupil L, Neelapu S, Flowers C, Dabaja BS. Assessment of Radiation Doses Delivered to Organs at Risk Among Patients With Early-Stage Favorable Hodgkin Lymphoma Treated With Contemporary Radiation Therapy. JAMA Netw Open 3(9):e2013935, 2020. e-Pub 2020. PMID: 32990738.
48. Chin CK, Nastoupil LJ. Novel Agents Beyond Immunomodulatory Agents and Phosphoinositide-3-Kinase for Follicular Lymphoma. Hematol Oncol Clin North Am 34(4):743-756, 2020. e-Pub 2020. PMID: 32586578.
49. Strati P, Nastoupil LJ, Davis RE, Fayad LE, Fowler N, Hagemeister FB, Kwak L, Oki Y, Wang M, Westin J, Ruben CE, Wesson ET, Piekarz R, Fanale MA, Lee HJ. A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas. Haematologica 105(1):e26-e28, 2020. e-Pub 2019. PMID: 31073068.
50. Andraos TY, Ayoub Z, Nastoupil LJ, Milgrom SA, Pinnix CC, Ng SP, Gunther JR, Fowler NH, Neelapu SS, Samaniego F, Fayad LE, Dabaja BS. Additional therapy improves outcomes in completely resected, limited-stage follicular lymphoma. Leuk Lymphoma 60(13):1-8, 2019. e-Pub 2019. PMID: 31234671.
51. Ayoub Z, Andraos T, Milgrom SA, Pinnix CC, Dabaja BS, Ng SP, Gunther JR, Khoury JD, Fowler NH, Neelapu SS, Samaniego F, Fayad LE, Nastoupil LJ. Limited stage grade 3 follicular lymphoma patients can experience favorable outcomes with combined modality therapy. Leuk Lymphoma 60(10):1-9, 2019. e-Pub 2019. PMID: 30942648.
52. Zackon AYL, Ayers AA, Yeager KA, Somma ML, Friedberg JW, Flowers CR, Nastoupil LJ. Maximizing the effectiveness of oral therapies in lymphoid cancers: research gaps and unmet needs. Leuk Lymphoma 60(10):1-9, 2019. e-Pub 2019. PMID: 31164024.
53. Pinnix CC, Gunther JR, Milgrom SA, Cruz Chamorro RJ, Medeiros LJ, Khoury JD, Amini B, Neelapu S, Lee HJ, Westin J, Fowler N, Nastoupil L, Dabaja B. Outcomes After Reduced-Dose Intensity Modulated Radiation Therapy for Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma. Int J Radiat Oncol Biol Phys 104(2):447-455, 2019. e-Pub 2019. PMID: 30769175.
54. Andraos T, Ayoub Z, Nastoupil L, Pinnix C, Milgrom S, Gunther J, Ng SP, Fowler N, Neelapu S, Samaniego F, Dabaja B. Early Stage Extranodal Follicular Lymphoma: Characteristics, Management, and Outcomes. Clin Lymphoma Myeloma Leuk 19(6):381-389, 2019. e-Pub 2019. PMID: 30935940.
55. Becnel MR, Nastoupil LJ, Samaniego F, Davis RE, You MJ, Green M, Hagemeister FB, Fanale MA, Fayad LE, Westin JR, Wang M, Oki Y, Forbes SG, Feng L, Neelapu SS, Fowler NH. Lenalidomide plus rituximab (R2 ) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial. Br J Haematol 185(5):874-882, 2019. e-Pub 2019. PMID: 30919940.
56. Strati P, Nastoupil LJ, Fayad LE, Samaniego F, Adkins S, Neelapu SS. Safety of CAR T-cell therapy in patients with B-cell lymphoma and chronic hepatitis B or C virus infection. Blood 133(26):2800-2802, 2019. e-Pub 2019. PMID: 31101626.
57. Chihara D, Oki Y, Fanale MA, Westin JR, Nastoupil LJ, Neelapu S, Fayad L, Fowler NH, Cheah CY. Stage I non-Hodgkin lymphoma: no plateau in disease-specific survival ?. Ann Hematol 98(5):1169-1176, 2019. e-Pub 2019. PMID: 30617643.
58. Pemmaraju N, Kantarjian H, Nastoupil L, Dupuis M, Zhou L, Pierce S, Patel KP, Masarova L, Cortes J, Verstovsek S. Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy. Blood 133(21):2348-2351, 2019. e-Pub 2019. PMID: 30796023.
59. Pinnix CC, Dabaja BS, Milgrom SA, Smith GL, Abou Yehia Z, Nastoupil L, Romaguera J, Turturro F, Fowler N, Fayad L, Westin J, Neelapu S, Fanale MA, Rodriguez MA, Hagemeister F, Lee HJ, Oki Y, Wang M, Samaniego F, Chi L, Esmaeli B. Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma. Head Neck 41(5):1546, 2019. e-Pub 2019. PMID: 30990235.
60. Pinnix CC, Milgrom SA, Cheah CY, Gunther JR, Ludmir EB, Wogan CF, Nastoupil LJ, Neelapu SS, Westin J, Lee HJ, Iyer SP, Steiner RE, Fayad LE, Fowler NH, Wang ML, Samaniego F, Rodriguez MA, Rich AE, Medeiros LJ, Dabaja BS. Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphoma. Blood Adv 3(9):1356-1367, 2019. PMID: 31036721.
61. Chihara D, Oki Y, Fanale MA, Westin JR, Nastoupil LJ, Neelapu S, Fayad L, Fowler NH, Cheah CY. Stage I Non-Hodgkin Lymphoma: difference in survival outcome by primary extranodal site of involvement. Br J Haematol 185(2):334-338, 2019. e-Pub 2018. PMID: 29978452.
62. Ludmir EB, Milgrom SA, Pinnix CC, Gunther JR, Westin J, Fayad LE, Khoury JD, Medeiros LJ, Dabaja BS, Nastoupil LJ. Emerging Treatment Strategies for Primary Breast Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue. Clin Lymphoma Myeloma Leuk 19(4):244-250, 2019. e-Pub 2019. PMID: 30686775.
63. Hill BT, Nastoupil L, Winter AM, Becnel MR, Cerhan JR, Habermann TM, Link BK, Maurer MJ, Fakhri B, Reddy P, Smith SD, Mukhija D, Jagadeesh D, Desai A, Alderuccio JP, Lossos IS, Mehra P, Portell CA, Goldman ML, Calzada O, Cohen JB, Hussain MJ, Ghosh N, Caimi P, Tiutan T, Martin P, Kodali A, Evens AM, Kahl BS. Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma. Br J Haematol 184(4):524-535, 2019. e-Pub 2018. PMID: 30575016.
64. Nastoupil LJ, Lunning MA, Vose JM, Schreeder MT, Siddiqi T, Flowers CR, Cohen JB, Burger JA, Wierda WG, O'Brien S, Sportelli P, Miskin HP, Purdom MA, Weiss MS, Fowler NH. Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial. Lancet Haematol 6(2):e100-e109, 2019. PMID: 30709431.
65. Yoder AK, Gunther JR, Milgrom SA, Mirkovic D, Nastoupil L, Neelapu S, Fanale M, Fowler N, Westin J, Lee HJ, Rodriguez MA, Iyer SP, Fayad L, Nieto YL, Hosing C, Ahmed S, Medeiros LJ, Khoury JD, Garg N, Amini B, Dabaja BS, Pinnix CC. Hitting a Moving Target: Successful Management of Diffuse Large B-cell Lymphoma Involving the Mesentery With Volumetric Image-guided Intensity Modulated Radiation Therapy. Clin Lymphoma Myeloma Leuk 19(1):e51-e61, 2019. e-Pub 2018. PMID: 30360985.
66. Monga N, Nastoupil L, Garside J, Quigley J, Hudson M, O'Donovan P, Parisi L, Tapprich C, Thieblemont C. Burden of illness of follicular lymphoma and marginal zone lymphoma. Ann Hematol 98(1):175-183, 2019. e-Pub 2018. PMID: 30315345.
67. Ludmir EB, Milgrom SA, Pinnix CC, Gunther JR, Westin J, Oki Y, Fayad LE, Medeiros LJ, Dabaja BS, Nastoupil LJ. Primary breast diffuse large B-cell lymphoma: treatment strategies and patterns of failure. Leuk Lymphoma 59(12):1-8, 2018. e-Pub 2018. PMID: 29697005.
68. Nastoupil LJ, Prasad V, Flowers CR. The need to assess financial adverse events. Lancet Haematol 5(11):e508-e509, 2018. e-Pub 2018. PMID: 29907551.
69. Leonard JP, Nastoupil LJ, Flowers CR. Where to start? Upfront therapy for follicular lymphoma in 2018. Hematology Am Soc Hematol Educ Program 2018(1):185-188, 2018. PMID: 30504308.
70. Nastoupil LJ, Flowers CR, Leonard JP. Sequencing of therapies in relapsed follicular lymphoma. Hematology Am Soc Hematol Educ Program 2018(1):189-193, 2018. PMID: 30504309.
71. Flowers CR, Leonard JP, Nastoupil LJ. Novel immunotherapy approaches to follicular lymphoma. Hematology Am Soc Hematol Educ Program 2018(1):194-199, 2018. PMID: 30504310.
72. Sheu T, Milgrom SA, Andraos TY, Gunther JR, Chi L, Nastoupil L, Fowler N, Oki Y, Fanale MA, Fayad LE, Hagemeister F, Neelapu SS, Medeiros LJ, Hosing C, Nieto Y, Ahmed S, Alousi AM, Dabaja B, Pinnix CC. Response-adapted radiation therapy for newly diagnosed primary diffuse large B-cell lymphoma of the CNS treated with methotrexate-based systemic therapy. Adv Radiat Oncol 3(4):639-646, 2018. e-Pub 2018. PMID: 30370365.
73. Nastoupil LJ. Next-generation therapy for follicular lymphoma. Blood 132(14):1465-1467, 2018. PMID: 30287467.
74. Jain P, Kanagal-Shamanna R, San Lucas FA, Nastoupil L, Romaguera J, Fayad L, Oki Y, Westin JR, Medeiros LJ, Wang M, Fowler N. Clinicopathological characteristics, outcomes and pattern of mutations in patients with follicular lymphoma who progressed on Bruton tyrosine kinase inhibitors. Br J Haematol 182(5):718-723, 2018. e-Pub 2017. PMID: 28771675.
75. Strati P, Chihara D, Oki Y, Fayad LE, Fowler N, Nastoupil L, Romaguera JE, Samaniego F, Garg N, Feng L, Wesson ET, Ruben CE, Stafford MD, Nieto Y, Khouri IF, Hosing C, Horowitz SB, Kamble RT, Fanale MA. A phase I study of romidepsin and ifosfamide, carboplatin, etoposide for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Haematologica 103(9):e416-e418, 2018. e-Pub 2018. PMID: 29622656.
76. Goldstein JS, Nastoupil LJ, Han X, Jemal A, Ward E, Flowers CR. Disparities in survival by insurance status in follicular lymphoma. Blood 132(11):1159-1166, 2018. e-Pub 2018. PMID: 30042094.
77. Taplitz RA, Kennedy EB, Bow EJ, Crews J, Gleason C, Hawley DK, Langston AA, Nastoupil LJ, Rajotte M, Rolston KV, Strasfeld L, Flowers CR. Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update. J Clin Oncol:JCO1800374. e-Pub 2018. PMID: 30179565.
78. Nastoupil LJ. Point: Can Chemotherapy Be Eliminated in the Treatment of Follicular Lymphoma?. Oncology (Williston Park) 32(8):404-7, 2018. PMID: 30153319.
79. Pinnix CC, Cella L, Andraos TY, Ayoub Z, Milgrom SA, Gunther J, Thosani S, Wogan C, Conson M, D'Avino V, Oki Y, Fanale M, Lee HJ, Neelapu S, Fayad L, Hagemeister F, Rodriguez MA, Nastoupil LJ, Nieto Y, Qiao W, Pacelli R, Dabaja B. Predictors of Hypothyroidism in Hodgkin Lymphoma Survivors After Intensity Modulated Versus 3-Dimensional Radiation Therapy. Int J Radiat Oncol Biol Phys 101(3):530-540, 2018. e-Pub 2018. PMID: 29681481.
80. Nastoupil LJ. Recent insights into large granular lymphocytic leukemia. Clin Adv Hematol Oncol 16(7):469-471, 2018. PMID: 30067616.
81. Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, Hallmeyer S, Holter Chakrabarty J, Leighl NB, Mammen JS, McDermott DF, Naing A, Nastoupil LJ, Phillips T, Porter LD, Puzanov I, Reichner CA, Santomasso BD, Seigel C, Spira A, Suarez-Almazor ME, Wang Y, Weber JS, Wolchok JD, Thompson JA, National Comprehensive Cancer Network. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 36(17):JCO2017776385, 2018. e-Pub 2018. PMID: 29442540.
82. Pinnix CC, Dabaja BS, Milgrom SA, Smith GL, Abou Z, Nastoupil L, Romaguera J, Turturro F, Fowler N, Fayad L, Westin J, Neelapu S, Fanale MA, Rodriguez MA, Hagemeister F, Ju Lee H, Oki Y, Wang M, Samaniego F, Chi L, Esmaeli B. Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma. Head Neck 40(6):1335, 2018. e-Pub 2018. PMID: 29851218.
83. Pinnix CC, Ng AK, Dabaja BS, Milgrom SA, Gunther JR, Fuller CD, Smith GL, Abou Yehia Z, Qiao W, Wogan CF, Akhtari M, Mawlawi O, Medeiros LJ, Chuang HH, Martin-Doyle W, Armand P, LaCasce AS, Oki Y, Fanale M, Westin J, Neelapu S, Nastoupil L. Positron emission tomography-computed tomography predictors of progression after DA-R-EPOCH for PMBCL. Blood Adv 2(11):1334-1343, 2018. PMID: 29895624.
84. Loghavi S, Medeiros LJ, Javadi S, Lin P, Khoury JD, Nastoupil L, Hunt KK, Clemens MW, Miranda RN. Breast Implant-Associated Anaplastic Large Cell Lymphoma With Bone Marrow Involvement. Aesthet Surg J 38(7), 2018. PMID: 29635424.
85. Chihara D, Fowler NH, Oki Y, Fanale MA, Nastoupil LJ, Westin JR, Fayad LE, Neelapu SS, Cheah CY. Impact of histologic subtypes and treatment modality among patients with primary central nervous system lymphoma: a SEER database analysis. Oncotarget 9(48):28897-28902, 2018. e-Pub 2018. PMID: 29988979.
86. Taplitz RA, Kennedy EB, Bow EJ, Crews J, Gleason C, Hawley DK, Langston AA, Nastoupil LJ, Rajotte M, Rolston K, Strasfeld L, Flowers CR. Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update. J Clin Oncol 36(14):JCO2017776211, 2018. e-Pub 2018. PMID: 29461916.
87. Becnel MR, Nastoupil LJ. Follicular Lymphoma: Past, Present, and Future. Curr Treat Options Oncol 19(7):32, 2018. e-Pub 2018. PMID: 29796824.
88. Jain P, Romaguera J, Srour SA, Lee HJ, Hagemeister F, Westin J, Fayad L, Samaniego F, Badillo M, Zhang L, Nastoupil L, Kanagal-Shamanna R, Fowler N, Wang ML. Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL). Br J Haematol. e-Pub 2018. PMID: 29785709.
89. Hu B, Younes A, Westin JR, Turturro F, Claret L, Feng L, Fowler N, Neelapu S, Romaguera J, Hagemeister FB, Rodriguez MA, Samaniego F, Fayad LE, Copeland AR, Nastoupil LJ, Nieto Y, Fanale MA, Oki Y. Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma. Leuk Lymphoma 59(4):1-8, 2018. e-Pub 2017. PMID: 28792260.
90. Guidot DM, Switchenko JM, Nastoupil LJ, Koff JL, Blum KA, Maly J, Flowers CR, Cohen JB. Surveillance imaging in mantle cell lymphoma in first remission lacks clinical utility. Leuk Lymphoma 59(4):1-8, 2018. e-Pub 2017. PMID: 28797213.
91. Milgrom SA, Pinnix CC, Chi TL, Vu TH, Gunther JR, Sheu T, Fowler N, Westin JR, Nastoupil LJ, Oki Y, Fayad LE, Neelapu S, Rodriguez MA, Hagemeister FB, Fanale MA, Lee HJ, Hosing C, Ahmed S, Nieto Y, Shpall EJ, Dabaja BS. Radiation Therapy as an Effective Salvage Strategy for Secondary CNS Lymphoma. Int J Radiat Oncol Biol Phys 100(5):1146-1154, 2018. e-Pub 2018. PMID: 29452771.
92. Pinnix CC, Wirth A, Milgrom SA, Andraos TY, Aristophanous M, Pham M, Hancock D, Ludmir EB, Gunther JR, Fanale MA, Oki Y, Nastoupil L, Chuang HH, Mikhaeel NG, Dabaja BS. Omitting cardiophrenic lymph nodes in the treatment of patients with Hodgkin lymphoma via modified involved-site radiation therapy. Leuk Lymphoma:1-10. e-Pub 2018. PMID: 29616834.
93. Strati P, Fowler N, Pina-Oviedo S, Medeiros LJ, Overman MJ, Romaguera JE, Nastoupil L, Wang M, Hagemeister FB, Rodriguez A, Oki Y, Westin J, Turturro F, Neelapu SS, Fayad L. Long-Term Remissions of Patients With Follicular Lymphoma Grade 3 Treated With R-CHOP. Clin Lymphoma Myeloma Leuk 18(1):e103-e108, 2018. e-Pub 2017. PMID: 29196178.
94. Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez MA, Wang M, Fowler NH, Davis RE, Medeiros LJ, Oki Y. The risk of central nervous system relapses in patients with peripheral T-cell lymphoma. PLoS One 13(3):e0191461, 2018. e-Pub 2018. PMID: 29538376.
95. Ludmir EB, Gutschenritter T, Pinnix CC, Gunther JR, Nastoupil LJ, Khoury JD, Medeiros LJ, Dabaja BS, Milgrom SA. Coincident primary breast lymphoma and gastrointestinal stromal tumor: case series and molecular mechanisms. Onco Targets Ther 11:8937-8942, 2018. e-Pub 2018. PMID: 30573980.
96. Ho JC, Dabaja BS, Milgrom SA, Smith GL, Reddy JP, Mazloom A, Young KH, Deng L, Medeiros LJ, Dong W, Allen PK, Andraos TY, Fowler NH, Nastoupil LJ, Oki Y, Fayad LE, Turturro F, Neelapu SS, Westin J, Hagemeister FB, Rodriguez MA, Pinnix CC. Radiation therapy improves survival in patients with testicular diffuse large B-cell lymphoma(). Leuk Lymphoma 58(12):1-12, 2017. e-Pub 2017. PMID: 28482717.
97. Pinnix CC, Dabaja BS, Milgrom SA, Smith GL, Abou Z, Nastoupil L, Romaguera J, Turturro F, Fowler N, Fayad L, Westin J, Neelapu S, Fanale MA, Rodriguez MA, Hagemeister F, Lee HJ, Oki Y, Wang M, Samaniego F, Chi L, Esmaeli B. Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma. Head Neck 39(6):1095-1100, 2017. e-Pub 2017. PMID: 28370694.
98. Lee HJ, Romaguera JE, Feng L, Desai AP, Zhang L, Fanale M, Samaniego F, Hagemeister FB, Fayad LE, Rodriguez MA, Medeiros JL, Hartig K, Nomie K, Ahmed M, Badillo M, Ye H, Oki Y, Lin P, Nastoupil L, Westin J, Wang M. Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell Lymphoma. Oncologist 22(5):549-553, 2017. e-Pub 2017. PMID: 28408615.
99. Fanale MA, Cheah CY, Rich A, Medeiros LJ, Lai CM, Oki Y, Romaguera JE, Fayad L, Hagemeister FB, Samaniego F, Rodriguez MA, Neelapu SS, Lee HJ, Nastoupil L, Fowler N, Turturro F, Westin J, Wang M, McLaughlin P, Pinnix C, Milgrom S, Dabaja B, Horowitz SB, Younes A. Encouraging activity for R-CHOP in Advanced Stage Nodular Lymphocyte Predominant Hodgkin Lymphoma. Blood. e-Pub 2017. PMID: 28522441.
100. Nastoupil LJ, McLaughlin P, Feng L, Neelapu SS, Samaniego F, Hagemeister FB, Ayala A, Romaguera JE, Goy AH, Neal E, Wang M, Fayad L, Fanale MA, Oki Y, Westin JR, Rodriguez MA, Cabanillas F, Fowler NH. High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study. Br J Haematol 177(2):263-270, 2017. e-Pub 2017. PMID: 28340281.
101. Jain P, Milgrom SA, Patel KP, Nastoupil L, Fayad L, Wang M, Pinnix CC, Dabaja BS, Smith GL, Yu J, Hu S, Bueso Ramos CE, Kanagal-Shamanna R, Medeiros LJ, Oki Y, Fowler N. Characteristics, management, and outcomes of patients with follicular dendritic cell sarcoma. Br J Haematol. e-Pub 2017. PMID: 28382648.
102. Casulo C, Nastoupil L, Fowler NH, Friedberg JW, Flowers CR. Unmet needs in the first-line treatment of follicular lymphoma. Ann Oncol. e-Pub 2017. PMID: 28430865.
103. Han X, Jemal A, Hulland E, Simard EP, Nastoupil L, Ward E, Flowers CR. HIV infection and survival of lymphoma patients in the era of highly active antiretroviral therapy. Cancer Epidemiol Biomarkers Prev 26(3):303-311, 2017. e-Pub 2016. PMID: 27756777.
104. Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez MA, Wang M, Fowler NH, Davis RE, Medeiros LJ, Hosing C, Nieto YL, Oki Y. The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma. Br J Haematol 176(5):750-758, 2017. e-Pub 2016. PMID: 27983760.
105. Cheah CY, Nastoupil LJ, McLaughlin P, Fanale MA, Neelapu SS, Fayad LE, Hagemeister FB, Fowler NH. Premature closure of a phase II study of bendamustine, mitoxantrone and rituximab for patients with untreated high-risk follicular lymphoma due to severe haematological and infectious toxicity. Br J Haematol 175(3):531-533, 2016. e-Pub 2015. PMID: 26683805.
106. Rai A, Nastoupil LJ, Williams JN, Lipscomb J, Ward KC, Howard DH, Lee D, Flowers CR. Patterns of use and survival outcomes of positron emission tomography for initial staging in elderly follicular lymphoma patients. Leuk Lymphoma:1-11. e-Pub 2016. PMID: 27830968.
107. Chihara D, Westin JR, Oki Y, Ahmed MA, Do B, Fayad LE, Hagemeister FB, Romaguera JE, Fanale MA, Lee HJ, Turturro F, Samaniego F, Neelapu SS, Rodriguez MA, Fowler NH, Wang M, Davis RE, Nastoupil LJ. Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma. Cancer 122(20):3145-3151, 2016. e-Pub 2016. PMID: 27351173.
108. Chen Y, Neelapu S, Feng L, Bi W, Yang TH, Wang M, Fanale MA, Westin JR, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Fowler NH, McLaughlin P, Cabanillas F, Oki Y, Nastoupil LJ, Rodriguez A. Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum β2-microglobulin level in patients with diffuse large b-cell lymphoma: a new prognostic model. Br J Haematol 175(2):290-299, 2016. e-Pub 2016. PMID: 27448187.
109. Bulka C, Nastoupil LJ, Koff JL, Bernal-Mizrachi L, Ward KC, Williams JN, Bayakly AR, Switchenko JM, Waller LA, Flowers CR. Relations Between Residential Proximity to EPA-Designated Toxic Release Sites and Diffuse Large B-Cell Lymphoma Incidence. South Med J 109(10):606-614, 2016. PMID: 27706495.
110. Pinnix CC, Osborne EM, Chihara D, Lai P, Zhou S, Ramirez MM, Oki Y, Hagemeister FB, Rodriguez AM, Samaniego F, Fowler N, Romaguera JE, Turturro F, Fayad L, Westin JR, Nastoupil L, Neelapu SS, Cheah CY, Dabaja BS, Milgrom SA, Smith GL, Horace P, Milbourne A, Wogan CF, Ballas L, Fanale MA. Maternal and Fetal Outcomes After Therapy for Hodgkin or Non-Hodgkin Lymphoma Diagnosed During Pregnancy. JAMA Oncol 2(8):1065-9, 2016. e-Pub 2016. PMID: 27227654.
111. Cheah CY, Chihara D, Horowitz S, Sevin A, Oki Y, Zhou S, Fowler NH, Romaguera JE, Turturro F, Hagemeister FB, Fayad LE, Wang M, Neelapu SS, Nastoupil LJ, Westin JR, Rodriguez MA, Samaniego F, Anderlini P, Nieto Y, Fanale MA. Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes. Ann Oncol 27(7):1317-23, 2016. e-Pub 2016. PMID: 27091808.
112. Chihara D, Westin JR, Miranda RN, Cheah CY, Oki Y, Turturro F, Romaguera JE, Neelapu SS, Nastoupil LJ, Fayad LE, Rodriguez MA, Fowler NH, Orlowski RZ, Wang M, Hagemeister FB, Medeiros LJ, Fanale MA. Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma. Br J Haematol. e-Pub 2016. PMID: 27378601.
113. Cheah CY, Chihara D, Ahmed M, Davis RE, Nastoupil LJ, Phansalkar K, Hagemeister FB, Fayad LE, Westin JR, Oki Y, Fanale MA, Romaguera JE, Wang ML, Lee H, Turturro F, Samaniego F, Rodriguez MA, Neelapu SS, Fowler NH. Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era. Ann Oncol 27(5):895-901, 2016. e-Pub 2016. PMID: 26802151.
114. Fowler NH, Cheah CY, Gascoyne RD, Gribben J, Neelapu SS, Ghia P, Bollard C, Ansell S, Curran M, Wilson WH, O'Brien S, Grant C, Little R, Zenz T, Nastoupil LJ, Dunleavy K. Role of the tumor microenvironment in mature B-cell lymphoid malignancies. Haematologica 101(5):531-40, 2016. PMID: 27132279.
115. Chen Q, Ayer T, Nastoupil LJ, Koff JL, Staton AD, Chhatwal J, Flowers CR. Population-specific prognostic models are needed to stratify outcomes for African-Americans with diffuse large B-cell lymphoma. Leuk Lymphoma 57(4):1-26, 2016. e-Pub 2015. PMID: 26415108.
116. Nastoupil LJ, Sinha R, Byrtek M, Ziemiecki R, Zhou X, Taylor M, Friedberg JW, Link BK, Cerhan JR, Dawson K, Flowers CR. Outcomes following watchful waiting for stage II-IV follicular lymphoma patients in the modern era. Br J Haematol 172(5):724-34, 2016. e-Pub 2016. PMID: 26729445.
117. Pinnix CC, Shah JJ, Chuang H, Costelloe CM, Medeiros LJ, Wogan CF, Reed V, Smith GL, Milgrom S, Patel K, Huo J, Turturro F, Romaguera J, Fayad L, Oki Y, Fanale MA, Westin J, Nastoupil L, Hagemeister FB, Rodriguez A, Qazilbash M, Shah N, Bashir Q, Ahmed S, Nieto Y, Hosing C, Rohren E, Dabaja B. Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review. Clin Lymphoma Myeloma Leuk 16(3):122-8, 2016. e-Pub 2015. PMID: 26795083.
118. Clemens MW, Medeiros LJ, Butler CE, Hunt KK, Fanale MA, Horwitz S, Weisenburger DD, Liu J, Morgan EA, Kanagal-Shamanna R, Parkash V, Ning J, Sohani AR, Ferry JA, Mehta-Shah N, Dogan A, Liu H, Thormann N, DiNapoli A, Lade S, Piccolini J, Reyes R, Williams T, McCarthy CM, Hanson SE, Nastoupil LJ, Gaur R, Oki Y, Young KH, Miranda RN. Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant-Associated Anaplastic Large-Cell Lymphoma. J Clin Oncol. e-Pub 2015. PMID: 26628470.
119. Fowler NH, Nastoupil LJ, Hagemeister FB, Neelapu SS, Fayad LE, LeBlanc D, Samaniego F, Cheah CY. Characteristics and management of rash following lenalidomide and rituximab in patients with untreated indolent non-Hodgkin lymphoma. Haematologica. e-Pub 2015. PMID: 26250576.
120. Cohen JB, Switchenko JM, Koff JL, Sinha R, Kaufman JL, Khoury HJ, Bumpers N, Colbert A, Hutchison-Rzepka A, Nastoupil LJ, Heffner LT, Langston AA, Lechowicz MJ, Lonial S, Flowers CR. A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphoma. Br J Haematol. e-Pub 2015. PMID: 26248505.
121. Nastoupil LJ, Neelapu SS. Novel immunologic approaches in lymphoma: unleashing the brakes on the immune system. Curr Oncol Rep 17(7):456, 2015. PMID: 25986722.
122. Flowers CR, Nastoupil LJ. Identifying racial differences in nodular lymphocyte-predominant Hodgkin lymphoma. Cancer. e-Pub 2015. PMID: 26149195.
123. Koff JL, Chihara D, Phan A, Nastoupil LJ, Williams JN, Flowers CR. To Each Its Own: Linking the Biology and Epidemiology of NHL Subtypes. Curr Hematol Malig Rep. e-Pub 2015. PMID: 26104907.
124. Pinnix CC, Dabaja B, Ahmed MA, Chuang HH, Costelloe C, Wogan CF, Reed V, Romaguera JE, Neelapu S, Oki Y, Rodriguez MA, Fayad L, Hagemeister FB, Nastoupil L, Turturro F, Fowler N, Fanale MA, Nieto Y, Khouri IF, Ahmed S, Medeiros LJ, Davis RE, Westin J. Single-Institution Experience in the Treatment of Primary Mediastinal B Cell Lymphoma Treated With Immunochemotherapy in the Setting of Response Assessment by (18)Fluorodeoxyglucose Positron Emission Tomography. Int J Radiat Oncol Biol Phys 92(1):113-121, 2015. PMID: 25863759.
125. Pinnix CC, Smith GL, Milgrom S, Osborne EM, Reddy JP, Akhtari M, Reed V, Arzu I, Allen PK, Wogan CF, Fanale MA, Oki Y, Turturro F, Romaguera J, Fayad L, Fowler N, Westin J, Nastoupil L, Hagemeister FB, Rodriguez MA, Ahmed S, Nieto Y, Dabaja B. Predictors of Radiation Pneumonitis in Patients Receiving Intensity Modulated Radiation Therapy for Hodgkin and Non-Hodgkin Lymphoma. Int J Radiat Oncol Biol Phys 92(1):175-182, 2015. PMID: 25863764.
126. Cheah CY, Nastoupil LJ, Neelapu SS, Forbes SG, Oki Y, Fowler NH. Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma. Blood 125(21):3357-9, 2015. PMID: 25999447.
127. Chihara D, Nastoupil LJ, Williams JN, Lee P, Koff JL, Flowers CR. New insights into the epidemiology of non-Hodgkin lymphoma and implications for therapy. Expert Rev Anticancer Ther:1-14. e-Pub 2015. PMID: 25864967.
128. Chen Q, Ayer T, Nastoupil LJ, Rose AC, Flowers CR. Comparing the Cost-Effectiveness of Rituximab Maintenance and Radioimmunotherapy Consolidation versus Observation Following First-Line Therapy in Patients with Follicular Lymphoma. Value Health 18(2):189-97, 2015. PMID: 25773554.
129. Oki Y, Younes A, Knickerbocker J, Samaniego F, Nastoupil L, Hagemeister F, Romaguera J, Fowler N, Kwak L, Westin J. Experience with HSP90 inhibitor AUY922 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma. Haematologica. e-Pub 2015. PMID: 25820332.
130. Williams JN, Rai A, Lipscomb J, Koff JL, Nastoupil LJ, Flowers CR. Disease characteristics, patterns of care, and survival in very elderly patients with diffuse large B-cell lymphoma. Cancer. e-Pub 2015. PMID: 25675909.
131. Abramson JS, Feldman T, Kroll-Desrosiers AR, Muffly LS, Winer E, Flowers CR, Lansigan F, Nabhan C, Nastoupil LJ, Nath R, Goy A, Castillo JJ, Jagadeesh D, Woda B, Rosen ST, Smith SM, Evens AM. Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy. Ann Oncol 25(11):2211-7, 2014. e-Pub 2014. PMID: 25193992.
132. Nastoupil LJ, Sinha R, Byrtek M, Ziemiecki R, Taylor M, Friedberg JW, Koff JL, Link BK, Cerhan JR, Dawson KL, Flowers CR. Comparison of the effectiveness of frontline chemoimmunotherapy regimens for follicular lymphoma used in the United States. Leuk Lymphoma 55(5):1295-1302. e-Pub 2014. PMID: 25263322.
133. Fowler NH, Davis RE, Rawal S, Nastoupil L, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale MA, Fayad LE, Westin JR, Shah J, Orlowski RZ, Wang M, Turturro F, Oki Y, Claret LC, Feng L, Baladandayuthapani V, Muzzafar T, Tsai KY, Samaniego F, Neelapu SS. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol 15(12):1311-8, 2014. e-Pub 2014. PMID: 25439689.
134. Westin JR, McLaughlin P, Romaguera J, Hagemeister FB, Pro B, Dang NH, Samaniego F, Rodriguez MA, Fayad L, Oki Y, Fanale M, Fowler N, Nastoupil L, Feng L, Loyer E, Younes A. Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage program for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. Br J Haematol 167(2):177-84, 2014. e-Pub 2014. PMID: 25039868.
135. Oki Y, Noorani M, Lin P, Davis RE, Neelapu SS, Ma L, Ahmed M, Rodriguez MA, Hagemeister FB, Fowler N, Wang M, Fanale MA, Nastoupil L, Samaniego F, Lee HJ, Dabaja BS, Pinnix CC, Medeiros LJ, Nieto Y, Khouri I, Kwak LW, Turturro F, Romaguera JE, Fayad LE, Westin JR. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol 166(6):891-901, 2014. e-Pub 2014. PMID: 24943107.
136. Nastoupil LJ. Routine use of maintenance therapy in follicular lymphoma: the strategy is effective, raising the question, 'what is the most important measure of success in the current era?'. Oncology (Williston Park) 28(9), 2014. PMID: 25224478.
137. Nastoupil LJ, Shenoy PJ, Ambinder A, Koff JL, Nooka AK, Waller EK, Langston A, Seward M, Kaufman JL, Bernal-Mizrachi L, King N, Lechowicz MJ, Lonial S, Sinha R, Flowers CR. Intensive chemotherapy and consolidation with high dose therapy and autologous stem cell transplant in patients with mantle cell lymphoma. Leuk Lymphoma:1-20. e-Pub 2014. PMID: 24828864.
138. Nastoupil LJ, Sinha R, Byrtek M, Zhou X, Taylor MD, Friedberg JW, Link BK, Cerhan JR, Dawson K, Flowers CR. The use and effectiveness of rituximab maintenance in patients with follicular lymphoma diagnosed between 2004 and 2007 in the United States. Cancer 120(12):1830-7, 2014. e-Pub 2014. PMID: 24668580.
139. Flowers CR, Nastoupil LJ. Socioeconomic disparities in lymphoma. Blood 123(23):3530-1, 2014. PMID: 24904097.
140. Read JA, Koff JL, Nastoupil LJ, Williams JN, Cohen JB, Flowers CR. Evaluating Cell-of-Origin Subtype Methods for Predicting Diffuse Large B-Cell Lymphoma Survival: A Meta-Analysis of Gene Expression Profiling and Immunohistochemistry Algorithms. Clin Lymphoma Myeloma Leuk 14(6):460-467. e-Pub 2014. PMID: 25052052.
141. Han X, Jemal A, Flowers CR, Sineshaw H, Nastoupil LJ, Ward E. Insurance status is related to diffuse large B-cell lymphoma survival. Cancer 120(8):1220-7, 2014. e-Pub 2014. PMID: 24474436.
142. Nastoupil LJ, Koff JL, Flowers CR. Novel therapies in mantle cell lymphoma: a pathway to chemotherapy-free strategies. Oncology (Williston Park) 27 Suppl 2:8-12, 2013. PMID: 25374999.
143. Bulka C, Nastoupil LJ, McClellan W, Ambinder A, Phillips A, Ward K, Bayakly AR, Switchenko JM, Waller L, Flowers CR. Residence proximity to benzene release sites is associated with increased incidence of non-Hodgkin lymphoma. Cancer 119(18):3309-17, 2013. e-Pub 2013. PMID: 23896932.
144. Nastoupil LJ, Sinha R, Flowers CR. The role of chemotherapy in managing chronic lymphocytic leukemia: optimizing combinations with targeted therapy. Expert Rev Anticancer Ther 13(9):1089-108, 2013. e-Pub 2013. PMID: 23919536.
145. Shi Z, Das S, Okwan-Duodu D, Esiashvili N, Flowers C, Chen Z, Wang X, Jiang K, Nastoupil LJ, Khan MK. Patterns of failure in advanced stage diffuse large B-cell lymphoma patients after complete response to R-CHOP immunochemotherapy and the emerging role of consolidative radiation therapy. Int J Radiat Oncol Biol Phys 86(3):569-77, 2013. e-Pub 2013. PMID: 23540349.
146. Ambinder AJ, Shenoy PJ, Nastoupil LJ, Flowers CR. Using primary site as a predictor of survival in mantle cell lymphoma. Cancer 119(8):1570-7, 2013. e-Pub 2013. PMID: 23341329.
147. Rose AC, Shenoy PJ, Garrett G, Seward M, Kucuk RA, Doksansky H, Nastoupil LJ, Flowers CR. A systematic literature review and meta-analysis of radioimmunotherapy consolidation for patients with untreated follicular lymphoma. Clin Lymphoma Myeloma Leuk 12(6):393-9, 2012. PMID: 23158095.
148. Nastoupil LJ, Flowers CR. Management of relapsed chronic lymphocytic leukemia: applying guidelines to practice. Community Oncol 9(12):S85-S92, 2012. PMID: 23316119.
149. Nastoupil L, Sinha R, Hirschey A, Flowers CR. Considerations in the initial management of follicular lymphoma. Community Oncol 9(11):S53-S60, 2012. PMID: 23544009.
150. Chen Q, Ayer T, Nastoupil LJ, Seward M, Zhang H, Sinha R, Flowers CR. Initial management strategies for follicular lymphoma. Int J Hematol Oncol 1(1):35-45, 2012. PMID: 23476737.
151. Flowers CR, Fedewa SA, Chen AY, Nastoupil LJ, Lipscomb J, Brawley OW, Ward EM. Disparities in the early adoption of chemoimmunotherapy for diffuse large B-cell lymphoma in the United States. Cancer Epidemiol Biomarkers Prev 21(9):1520-30, 2012. e-Pub 2012. PMID: 22771484.
152. Nastoupil LJ, Rose AC, Flowers CR. Diffuse large B-cell lymphoma: current treatment approaches. Oncology (Williston Park) 26(5):488-95, 2012. PMID: 22730604.
153. Nastoupil LJ, Sinha R, Flowers CR. Management Strategies for Elderly Patients with Diffuse Large B-Cell Lymphoma. Eur Oncol Haematol 8(2):123-126, 2012. PMID: 23805375.
154. Sinha R, Nastoupil L, Flowers CR. Treatment Strategies for Patients with Diffuse Large B-Cell Lymphoma: Past, Present, and Future. Blood Lymphat Cancer 2012(2):87-98, 2012. PMID: 23532092.
155. Ambinder AJ, Shenoy PJ, Malik N, Maggioncalda A, Nastoupil LJ, Flowers CR. Exploring risk factors for follicular lymphoma. Adv Hematol 2012:626035, 2012. e-Pub 2012. PMID: 23028387.
156. Flowers CR, Nastoupil LJ, Bernal-Mizrachi L, Rose AC, Sinha R. New Challenges in the Management of Diffuse Large B-Cell Lymphoma. Treat Strategies Hematol 2(1):68-73, 2012. PMID: 23805376.
157. Shenoy PJ, Malik N, Sinha R, Nooka A, Nastoupil LJ, Smith M, Flowers CR. Racial differences in the presentation and outcomes of chronic lymphocytic leukemia and variants in the United States. Clin Lymphoma Myeloma Leuk 11(6):498-506, 2011. e-Pub 2011. PMID: 21889433.

Invited Articles

1. Nastoupil L. Point: Can Chemotherapy Be Eliminated in the Treatment of Follicular Lymphoma?. Oncology (Williston Park) 32(8):404-407, 2018. PMID: 30153319.
2. Nastoupil L. Therapy Sequencing in Indolent Lymphoma. Current Treatment Options in Oncology.

Abstracts

1. Cherng H-JJ1, Sun R, Yang H, Deng Q, Fayad L, Fowler NH, Parmar S, Ahmed S, Steiner RE, Hagemeister FB, Lee HJ, Nair R, Rodriguez MA, Samaniego F, Iyer SP, Nastoupil L, Neelapu SS, Strati P, Westin JR, Green MR. A Risk Score Incorporating Low Pass Whole Genome Sequencing of Cell Free DNA from Patients Receiving CD19 CAR T-Cell Therapy for Large B-Cell Lymphoma. American Society of Hematology (Blood) 138(Suppl 1), 2021.
2. Spiegel JY, Jain MD, Nastoupil L, Tamaresis J, Ghobadi A, Lin Y, Lekakis LJ, Reagan PM, Oluwole OO, McGuirk JP, Deol A, Sehgal AR, Goy AH, Hill BT, Andreadis C, Muñoz J, Ulrickson ML, Westin JR, Chavez JC, Jacobs MT, Bennani NN, Rapoport AP, Vose JM, Miklos DB, Neelapu SS, Locke FL, Dahiya S, Lunning MA. Long-Term Outcomes of Patients with Large B-Cell Lymphoma Treated with Standard-of-Care Axicabtagene Ciloleucel: Results from the US Lymphoma CAR-T Cell Consortium. American Society of Hematology (Blood) 138(Suppl 1), 2021.
3. Riedell PA, Brower J, Nastoupil L, Perales M-A, Maziarz RT, McGuirk JP, Bachanova V, Hwang W-T, Schuster SJ, Bishop MR, Porter DL. A Multicenter Analysis of Outcomes, Toxicities, and Patterns of Use with Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B-Cell Lymphomas. American Society of Hematology (Blood) 138(Suppl 1), 2021.
4. Nair R, Feng L, Gunther JR, Xu J, Malpica-Castillo L, Huen A, Torres Cabala C, Heberton M, Fang P, Ahmed S, Miranda RN, Fayad L, Steiner R, Lee HJ, Chihara D, Jain P, Srour SA, Nieto Y, Nastoupil L, Pinnix CC, Neelapu SS, Flowers CR, Medeiros LJ, Hosing C, Wang M, Dabaja BS, Vega F, Iyer SP. Outcomes of Patients with Extranodal Natural Killer/T-Cell Lymphoma: Single Institution Series. American Society of Hematology (Blood) 138(Suppl 1), 2021.
5. Luan D, Flowers CR, Link BK, Friedberg JW, Cohen JB, Kahl BS, Lossos IS, Nastoupil L, Maurer MJ, Cerhan JR, Martin P. Evaluation of Eligibility Criteria in First-Line Clinical Trials for Follicular Lymphoma: A MER/LEO Database Analysis. American Society of Hematology (Blood) 138(Suppl 1), 2021.
6. Liu J, Narendranath E, Ghobadi A, Lazaryan A, Ibrahim U, Jacobson C, Naik SG, Olszewski AJ, Lin Y, Mullick Chowdhury S, Jacobs MT, Nastoupil L, Osman K, Ahmed S, Evens AM. Real World Evidence (RWE) of Safety, Efficacy, and Outcomes of CD19 CAR-T Therapy in 20 Patients with Solid Organ Transplant (SOT)-Related Post-Transplant Lymphoproliferative Disorder (PTLD). American Society of Hematology (Blood) 138(Suppl 1), 2021.
7. Al Zaki A, Westin JR, Watson G, Feng L, Ahmed S, Mistry H, Nastoupil L, Hawkins M, Nair R, Iyer SP, Lee H, Steiner RE, Flowers CR, Shpall EJ, Kebriaei P, Neelapu SS, Strati P. Analysis of Factors Associated with Conversion to CR in Patients with Large B-Cell Lymphoma Achieving Day 30 PR after CAR T-Cell Therapy. American Society of Hematology (Blood) 138(Suppl 1), 2021.
8. Budde LE, Sehn LH, Matasar MJ, Schuster SJ, Assouline S, Giri P, Kuruvilla J, Canales M, Dietrich S, Fay K, Ku M, Nastoupil L, Wei MC, Yin S, Doral MY, Li C-C, Huang H, Negricea R, Penuel E, O'Hear C, Bartlett NL. Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results from a Phase I/II Study. American Society of Hematology (Blood) 138(Suppl 1), 2021.
9. Thieblemont C, Dickinson M, Martinez-Lopez J, Kolstad A, Butler JP, Ghosh M, Popplewell LL, Chavez JC, Bachy E, Kato K, Harigae H, Jose Kersten M, Andreadis C, Riedell PA, Joy Ho P, Pérez-Simón J, Chen A, Nastoupil L, Von Tresckow B, Ferreri A-JM, Teshima T, Patten PEM, McGuirk JP, Petzer A, Offner F, Viardot A, Zinzani PL, Malladi R, Zia A, Lobetti Bodoni C, Masood A, Schuster SJ, Fowler NH, Dreyling MH. Efficacy of Tisagenlecleucel in Adult Patients (Pts) with High-Risk Relapsed/Refractory Follicular Lymphoma (r/r FL): Subgroup Analysis of the Phase II Elara Study. American Society of Hematology (Blood) 138(Suppl 1), 2021.
10. Budde E, Gopal AK, Kim WO, Flinn IW, Cheah CYY, Nastoupil L, Matasar MJ, Diefenbach CS, Gregory GP, Qazi I, Pang C-F, Leabman M, Hernandez G, Sison I, Keyt BA, Chen D, Armand P. T Cell Engager (TCE) in Patients with Advanced B-Cell Malignancies. American Society of Hematology (Blood) 138(Suppl 1), 2021.
11. Kitsada Wudhikarn, Ana Alarcon Tomas, Jamie Brower, Veronika Bachanova, Richard T. Maziarz, Joseph P. McGuirk, Loretta Nastoupil, David L. Porter, Peter A. Riedell, Miguel-Angel Perales. Outcomes of Aggressive B Cell Lymphoma Patients with No Evidence of Measurable Disease at the Time of CD19 Chimeric Antigen Receptor T Cell Therapy: The Experience from the CAR T Cell Consortium. American Society of Hematology (Blood) 138(Suppl 1), 2021.
12. Pinnix CC, Dabaja BS, Gunther JR, Fang P, Wu S, Nastoupil L, Strati P, Nair R, Ahmed S, Steiner RE, Malpica-Castillo L, Chihara D, Jain P, Fayad L, Westin JR, Neelapu SS, Rodriguez MA, Hagemeister FB, Lee HJ, Wang M, Samaniego F, Fowler NH, Flowers CR, Feng L, Chi L, Esmaeli B. Phase II Trial of Response Adapted Ultra Low Dose (ULD) Orbital Radiation Therapy for Indolent B Cell Lymphoma. American Society of Hematology (Blood) 138(Suppl 1), 2021.
13. Chihara D, Nastoupil L, Strati P, Samaniego F, Feng L, Rodriguez MA, Fayad L, Westin JR, Hagemeister FB, Wang M, Neelapu SS, Fowler NH. Ten Year Follow up of the MD Anderson Cancer Center Phase 2 Study of Rituximab in Combination with Lenalidomide (R2) for Patients with Low Tumor Burden Follicular Lymphoma. American Society of Hematology (Blood) 138(Suppl 1), 2021.
14. Westin JR, Steiner R, Feng L, Strati P, Flowers CR, Neelapu SS, Nastoupil L, Chihara D, Hagemeister FB, Ahmed S, Nair R, Fayad L, Lee HJ, Rodriguez MA, Davis E, Green MR. Smart Stop: A Phase II Study of Lenalidomide, Tafasitamab, Rituximab, and Acalabrutinib Alone and with Chemotherapy in Patients with Newly Diagnosed DLBCL. American Society of Hematology (Blood) 138(Suppl 1), 2021.
15. Michot J-M, Chavez JC, Carpio C, Ferrari S, Feldman TA, Morillo D, Kuruvilla J, Pinto A, Ribrag V, Bachy E, Buchholz TJ, Carrancio S, Guarinos C, Wu F, Li S, Patah P, Pourdehnad M, Nastoupil L. Clinical Activity of CC-99282, a Novel, Oral Small Molecule Cereblon E3 Ligase Modulator (CELMoD) Agent, in Patients (Pts) with Relapsed or Refractory Non-Hodgkin Lymphoma (R/R NHL) - First Results from a Phase 1, Open-Label Study. American Society of Hematology (Blood) 138(Suppl 1), 2021.
16. Batlevi CL, Park SI, Nastoupil L, Phillips T, Amengual JE, Andorsky D, Campbell P, McKay P, Pagel JM, Leonard JP, Yang J, O'Connor H, Hamlett A, Adib D, Morschhauser F. Interim Analysis of the Randomized Phase 1b/3 Study Evaluating the Safety and Efficacy of Tazemetostat Plus Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma. American Society of Hematology (Blood) 138(Suppl 1), 2021.
17. Morschhauser F, Nastoupil L, Feugier P, De Colella JMS, Tilly H, Lia Palomba M, Bachy E, Fruchart C, Libby E, Casasnovas R-O, Flinn IW, Haioun C, Maisonneuve H, Ysebaert L, Bartlett NL, Bouabdallah K, Brice P, Ribrag V, Le Gouill S, Daguindau N, Delwail V, Pica G-M, Garcia-Sancho AM, Lopez-Guillermo A, Larouche J-F, Ando K, da Silva Maria G, André M, Wu KL, Sehn LH, Izutsu K, Cartron G, Gkasiamis A, Crowe R, Xerri L, Fowler NH, Salles G. Six-Year Results from the Phase 3 Randomized Study Relevance Show Similar Outcomes for Previously Untreated Follicular Lymphoma Patients Receiving Lenalidomide Plus Rituximab (R 2 ) Versus Rituximab-Chemotherapy Followed By Rituximab Maintenance. American Society of Hematology (Blood) 138(Suppl 1), 2021.
18. Steiner RE, Strati P, Flowers CR, Neelapu SS, Green MR, Nastoupil L, Hagemeister FB, Feng L, Ahmed S, Nair R, Fayad L, Lee HJ, Rodriguez MA, Westin JR. Pacific: A Phase II Study of Brentuximab Vedotin and Nivolumab Alone and then Combined with Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Patients with Untreated Primary Mediastinal Large B-Cell Lymphoma. American Society of Hematology (Blood) 138(Suppl 1), 2021.
19. Nair R, Deen N, Ahmed S, Miranda RN, Fowler NH, Fayad L, Steiner RE, Hagemeister FB, Rodriguez MA, Lee HJ, Strati P, Malpica-Castillo L, Chihara D, Jain P, Gunther JR, Flowers CR, Medeiros LJ, Nieto Y, Ramdial JL, Neelapu SS, Nastoupil L, Green ML, Wang M, Vega F, Feng L, Iyer SP, Westin JR. Outcome of Patients with T- Cell Histiocyte Rich B Cell Lymphoma: Single Institution Series. American Society of Hematology (Blood) 138(Suppl 1), 2021.
20. Luan D, Flowers CR, Link BK, Friedberg JW, Cohen JB, Kahl BS, Lossos IS, Nastoupil L, Maurer MJ, Cerhan JR, Martin P. Evaluation of Eligibility Criteria in First-Line Clinical Trials for Follicular Lymphoma: A MER/LEO Database Analysis. American Society of Hematology (Blood) 138(Suppl 1), 2021.
21. Chen L, Xie J, Wu A, Liao L, Du EX, Noman A, Nastoupil LJ. Resource use and costs in patients with relapsed/refractory diffuse large C-cell lymphoma who initiated a third-line therapy in the post CAR-T era: A longitudinal outlook. Journal of Clinical Oncology 39(Suppl 15):abstr e19560, 2021.
22. Iyer SP, Xu J, Becnel MR, Nair R, Steiner R, Feng L, Lee JH, Strati P, Ahmed S, Parmar S, Nieto Y, Hosing C, Westin J, Nastoupil L, Vo A, Samaniego F, Fowler NH, Saini N, Khouri IF, Im JS, Jain p, Fayad L, Wang M, Miranda RN, Vega F, Flowers C, Neelapu SS. A Phase II Study of Pembrolizumab in Combination with Romidepsin Demonstrates Durable Responses in Relapsed or Refractory T-Cell Lymphoma (TCL). American Society of Hematology (Blood) 136(Suppl 1), 2020.
23. Assouline SE, Kim WS, Sehn LH, Schuster SJ, Chea CY, Nastoupil LJ, Shadman M, Yoon S-S, Matasar MJ, Diefenbach C, Gregory GP, Bartlett NL, Wei MC, Doral MY. Mosunetuzumab Shows Promising Efficacy in Patients with Multiply Relapsed Follicular Lymphoma: Updated Clinical Experience from a Phase I Dose-Escalation Trial. American Society of Hematology (Blood) 136(Suppl 1), 2020.
24. Strati P, Samaniego F, Gallardo M, Noorani M, Hagemeister FB, Westin JR, Lee HJ, Rodriguez MA, Neelapu SS, Gunther JR, Kangal-Shamanna R, Vega F, Fowler NH, Flowers CR, Nastoupil LJ. Treatment and Outcome of Patients with Follicular Lymphoma Relapsed or Progressed after Frontline Lenalidomide and Rituximab. American Society of Hematology (Blood) 136(Suppl 1), 2020.
25. Jain P, Tang G, Yin CC, Young C, Navsaria L, Badillo M, Chen W, Li Y, Che Y, Liu Y, Oriabure O, Nogueras Gonzales GM, Westin J, Nastoupil LJ, Ahmed S, Nair R, Thirumurthi S, Li S, Kangal-Shamanna R, Vega F, Flowers C, Wang M. Complex Karyotype Is a Significant Predictor for Worst Outcomes in Patients with Mantle Cell Lymphoma (MCL) Treated with BTK Inhibitors – Comprehensive Analysis of 396 Patients. American Society of Hematology (Blood) 136(Suppl 1), 2020.
26. Budde E, Gopal AK, Flinn IW, Nastoupil LJ, Gordon MS, Pang C-F, Keyt B, Carroll S, Leabman M, Hernandez G, Sison I, Chen D, Godfrey W, Armand P. Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class IgM Based Bispecific Antibody Igm-2323 (anti-CD20 x anti-CD3) in Patients with Advanced B-Cell Malignancies. American Society of Hematology (Blood) 136(Suppl 1), 2020.
27. Fowler NH, Dickinson M, Dreyling M, Martinez-Lopez J, KolstadA, Butler JP, Ghosh M, Popplewell LL, Chavez JC, Bachy E, Kato K, Harigae H, Kersten MJ, Andreadis C, Riedell PA, Ho PJ, Perez-Simon JA, Nagle SJ, Nastoupil LJ, vonTresckow B, Ferreri AJM, Teshima T, Pattern P, McGuirk JP, Petzer A, Offner F, Viardot A, Zinzani PL, Malladi R, Pacaudi LB, Forcina A, Zia A, Schuster SJ, Thieblemont C. Efficacy and Safety of Tisagenlecleucel in Adult Patients with Relapsed/Refractory Follicular Lymphoma: Interim Analysis of the Phase 2 Elara Trial. American Society of Hematology (Blood) 136(Suppl 1), 2020.
28. Srour SA, Xu J, Al-Juhaishi T, Steiner RE, Ensor J, Ahmed S, Parmar S, Strati P, Nastoupil LJ, Nieto Y, Hosing C, Lee HJ, Westin J, Fowler NH, Fayad L, Dabaja BS, Pinnix CC, Gunther JR, Fang P, Samaniego F, Jain P, Champlin RE, Khouri IF, Wang M, Miranda RN, Vega F, Neelapu SS, Flowers C, Iyer SP. Retrospective Review of Prognostic and Predictors Markers in Newly Diagnosed Angioimmunoblastic T Cell Lymphoma at UT MD Anderson Cancer Center. American Society of Hematology (Blood) 136(Suppl 1), 2020.
29. Wang M, Jain P, Yao Y, Liu Y, Zhao S, Hill, Moghrabi O, Lee HJ, Samaniego F, Westin J, Nastoupil JJ, Kangal-Shamanna R, Young C, Chen W, Oriabure O, Che Y, Li Y, Feng L, Nogueras Gonzalez GM Xu G, Wagner-Bartak N, Thirumurthi S, Santo D, Tang G, Vega F, Yin CC, Avellaneda M, Badillo M, Flowers C, Wang L. Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX in Patients (age ≤ 65 years) with Previously Untreated Mantle Cell Lymphoma – Phase-II Window-1 Clinical Trial. American Society of Hematology (Blood) 136(Suppl 1), 2020.
30. Mondello P, Strati S, Merryman RW, Joffee E, Ruella M, Seshan V, St Pierre F, Major A, Pophali P, Fiasconaro M, Ho CI, Neal E, Lai C-M, Spilberg G, Rajguru S, Svoboda J, Witzig TE, Smith SM, Armand P, Nastoupil LF, Ansell SM, Zelenetz AD, Younes A, Salles G. R-CHOP Versus R-Bendamustine with or without Rituximab Maintenance in Newly Diagnosed Follicular Lymphoma Patients with High SUV at Baseline PET. American Society of Hematology (Blood) 136(Suppl 1), 2020.
31. Jain P, Yao Y, Zhao S, Liu Y, Hill H, Che Y, Li Y, Jordan AA, McIntosh J, Lee HJ Steiner RE, Samaniego F, Westin J, Nastoupil LJ, Nair R, Ahmed S, Young C, Kangal-Shamanna R, Oriabure O, Xu G, Chen W, moghrabi O, McCalin FM, BAdillo M, Thirumurthi S, Santos D, IIiescu C, Yin CC, Li S, Tang G, Vega F, Neelapu SS, Flowers C, Wang L, Wang M. Combination of Ibrutinib with Rituximab (IR) in Previously Untreated Older Patients with Mantle Cell Lymphoma (MCL) – a Phase II Clinical Trial. American Society of Hematology (Blood) 136(Suppl 1), 2020.
32. Jain P, Zhang S, Kangal-Shamanna R, Navsaria L, Young C, Tang G, Yin CC, BAdillo M, Chen W, Oriabure O, Lee HJ, Westin J, Nastoupil LJ, Moghrabi O, Che Y, Samaniego F, Ahmed S, Nair R, Li S, Vega F, Flowers C, Wang L, Wang M. Outcomes of Acalabrutinib Failures in Relapsed Mantle Cell Lymphoma. American Society of Hematology (Blood) 136(Suppl 1), 2020.
33. Strati P, Mistry H, Pulsifer B, Fayad L, Ahmed S, Lee JH Iyer SP, Nair R, Nastoupil LJ, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Dabaja B, Noorani M, Claussen CM, Shpall EJ, Kebraei P, Flowers CR, Westin JR, Neelapu SS. Prognostic Value of Delta Lymphocyte Index (DLIx) in Patients with Large B-Cell Lymphoma (LBCL) Treated with Chimeric Antigen Receptor (CAR) T-Cell Therapy. American Society of Hematology (Blood) 136(Suppl 1), 2020.
34. Sani N, Chang C-C, Strati P, Nastoupil LJ, Westin J, Nair R, Fayad L, Ahmed S, Lee HJ, Iyer SP, Steiner RE, Greenbaum U, Kebriaei P, Shpall EJ, Jain N, Green MR, Ajami N, Flowers C. Gut Bacterial Diversity Associates with Efficacy of Anti-CD19 CAR T-Cell Therapy in Patients with Large B-Cell Lymphoma. American Society of Hematology (Blood) 136(Suppl 1), 2020.
35. Khouri IF, Milton DR, Ledesma C, Jabbour E, Bashir Q, Im JS, Fayad L, Lee JH, Nair R, Nastoupil LJ, Samaneigo F, Iyer SP, Flowers LJ, Samaniego F, Iyer SP, Flowers C, Champlin RE, Sharma P, Gulbis A. Maintenance Therapy with Ipilimumab Plus Lenalidomide after Autologous Stem Cell Transplantation for Patients with Lymphoma. American Society of Hematology (Blood) 136(Suppl 1), 2020.
36. Fitzgerald L, Kittai AS, Nastoupil LJ, Waller A, Jacobson C, Saucier A, Denlinger N, Kamdar M, Spradley J, Lynch RC, Chipman J, Hu B. Real World Outcomes of Elderly Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma Treated with Chimeric Antigen Receptor T Cell Therapy: An Updated Analysis. American Society of Hematology (Blood) 136(Suppl 1), 2020.
37. Gouni S, Strati P, Westin J, Nastoupil LJ, Steiner RE, Nair R, Fayad L, Neelapu SS, Landgraf R, Bilbao D, Vega F, Agarwal N. Use of Medium Potency Statins Is Associated with Improved Outcomes after Frontline RCHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL). American Society of Hematology (Blood) 136(Suppl 1), 2020.
38. Cherng H-JJ Steiner RE, Fayad L, Strati P, Nair R, Hagemeister FB, Nastoupil LJ, Lee JH, Neelapu SS, Flowers C, Samaniego F, Rodriguez MA, Feng L, Chuang H, Westin JR. Persistent Overall Response on Early PET/CT Scans during Salvage Therapy for Relapsed or Refractory DLBCL Predicts for Disease Specific Survival. American Society of Hematology (Blood) 136(Suppl 1), 2020.
39. Greenbaum U, Strati P, Saliba RM, Tores J, Rondon G, Nieto Y, Hosing C, Srour SA, Westin J, Fayad L, Lee HJ, Iyer SP, Nastoupil LJ, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Flowers C, Tummala S, Ramdial J, Yalniz FF, Hawkins M, Rezvani K, Champlin RE, Shpall EJ, Neelapu SS, Kebriaei P, Ahmed S. The Easix (Endothelial Activation and Stress Index) Score Predicts for CAR T Related Toxicity in Patients Receiving Axicabtagene Ciloleucel (axi-cel) for Non-Hodgkin Lymphoma (NHL). American Society of Hematology (Blood) 136(Suppl 1), 2020.
40. Khouri IF, Gruschkus SK, Gulbis A, Ledesma C, Jain N, Kadia TM, Pemmaraju N, Anderlini P, Bashir Q, Daher M, Kebriaei P, Marin D, Mehta Rohtesh, Popat RU, Saini N, Srour SA, Im JS, Fayad L, Nair R, Iyer SP, Strati P, Samaniego, Nastoupil LJ, Flowers C, Rondon G, Kantarjian HM, Champlin RE, Jabbour E. Nonmyeloablative Allogeneic Stem Cell Transplantation with or without Inotuzumab Ozogamicin for Lymphoid Malignancies. American Society of Hematology (Blood) 136(Suppl 1), 2020.
41. Nastoupil L. Axicabtagene ciloleucel (Axl-cel) CD19 chimeric antigen receptor (CAR)T-cell therapy for relapsed/refractory large b-cell lymphoma: Real world experience. Blood, 2018.
42. Nastoupil L. Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated subjects with follicular and marginal zone lymphoma: An open label, phase II study. Blood, 2018.
43. Nastoupil L. Avadomide (CC-12), a novel cereblon modulating agent, plus rituximab in patients with relapsed or refractory follicular lymphoma. Blood, 2018.
44. Fowler N, Neelapu S, Samaniego F, Forbes S, Hagemeister FB, Fayad L, Feng L, Turturro F, Westin JR, Arafat J, Neal E, Nastoupil LJ. Activity of the Immunologic Doublet of Lenalidomide Plus Obinutuzumab in Relapsed Follicular Lymphoma: Results of a Phase I/II Study. J Clin Oncol 35(15), 2017.
45. Westin JR, Oki Y, Fayad L, Nastoupil LJ, Turturro F, Hagemeister FB, Sathyanarayanan V, Young KH, McDonnell T, Chuang H, Zhou S, Neelapu SS, Davis RE. Rituximab, Lenalidomide, and Ibrutinib Alone and Combined with Dose Adjusted Chemotherapy for Patients with High Risk Diffuse Large B-cell Lymphoma. J Clin Oncol 34(15), 2017.
46. Hu B, Loghavi S, Fayad L, Noorani M, Fowler N, Hagemeister FB, Lee HJ, Nastoupil LJ, Neelapu S, Fanale MA, Samaniego F, Turturro F, Wang M, Davis RE, Westin JR, Medeiros LJ, Oki Y. Outcomes of De Novo CD5+ Diffuse Large B-Cell Lymphoma (DLBCL) in The Rituximab (R) Era. J Clin Oncol 35(15), 2017.
47. Nastoupil LJ, Westin JR, Fowler N, Fanale MA, Samaniego F, Oki Y, Obi C, Cao J, Cheng X, Ma MCJ, Wang Z, Chu F, Feng L, Zhou S, Davis RE, Neelapu S. Response Rates with Pembrolizumab in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma: Interim Results of an On Open-Label, Phase II Study. J Clin Oncol 35(15), 2017.
48. Fanale MA, Cheah CY, Rich A, Medeiros LJ, Lai Cm, Oki Y, Romaguera JE, Fayad LE, Hagemeister FB, Samaniego F, Rodriguez MA, Neelapu SS, Lee HJ, Nastoupil L, Fowler N, Turturro F, Westin JR, Wang ML, McLaughlin P, Pinnix CC, Milgrom SA, Dabaja B, Horowitz SB, Younes A. Encouraging Activity for R-CHOP in Advanced Stage Nodular Lymphocyte–predominant Hodgkin Lymphoma. Blood 130(4):472-477, 2017.
49. Khouri, IF, Turturro, F, Milton, DR, Korbling, M, Samuels, BI, Jabbour, EJ, Ledesma, C, Valverde, RB, Gao, H, Fanale, MA, Fayad, LE, Nastoupil, LJ, Reuben, JM, Gulbis, AM. Ofatumumab Plus Ifosfamide/Etoposide (OIE) Followed By Autologous Stem Cell Transplantation (ASCT) in Patients with b-Cell Non-Hodgkin's Lymphomas (NHL). Blood (2016 ASH Annual Meeting) 128(22):5814, 2016.
50. Hu, B, Younes, A, Claret, L, Feng, L, Westin, JR, Fowler, N, Neelapu, S, Hagemeister, FB, Rodriguez, MA, Samaniego, F, Fayad, LE, Nastoupil, LJ, Copeland, AR, Fanale, MA, Oki, Y. The Final Report of a Phase I/II Study of Panobinostat in Combination with ICE (Ifosfamide, Carboplatin and Etoposide) in Patients (pts) with Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL). Blood (2016 ASH Annual Meeting) 128(22):1833, 2016.
51. Fowler, N, Nastoupil, L, de Vos, S, Knapp, M, Flinn, IW, Chen, RW, Advani, RH, Bhatia, S, Martin, P, Mena, R, Suzuki, S, Beaupre, DM, Neuenburg, JK, Palomba ML. Ibrutinib Combined with Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Arm 1 + Arm 2 Results from a Multicenter, Open-Label Phase 2 Study. Blood (2016 ASH Annual Meeting) 128(22):1804, 2016.
52. Simar, KA, Sathyanarayanan, V, Issa, AK, Ahmed, MA, Noorani, M, Fanale, MA, Oki, Y, Hagemeister, FB, Neelapu, SS, Nastoupil, L, Fowler, N, Turturro, F, Davis, RE, Rodriguez, MA, Wang, M, Feng, L, Young, KH, McDonnell, TJ, Pinnix, CC, Fayad, LE, Westin, JR. Analyzing Patient Characteristics Who Received (DA) EPOCH-R for High Risk Diffuse Large B-Cell Lymphoma: MD Anderson Cancer Center Experience. Blood (2016 ASH Annual Meeting) 128(22):4208, 2016.
53. Westin, JR, Sathyanarayanan, V, Fayad, Nastoupil, LJ, Turturro, F, Hagemeister, FB, Simar, KA, Young, KH, McDonnell, TJ, Chuang, HH, Kamil, F, Feng, L, Davis, RE, Neelapu, SS, Oki, Y. Lenalidomide and Obinutuzumab with CHOP for Newly Diagnosed Diffuse Large B-Cell Lymphoma: Phase I Results. Blood (2016 ASH Annual Meeting) 128(22):5395, 2016.
54. Guidot, DM, Switchenko, J, Nastoupil, LJ, Koff, JL, Flowers, C, Cohen, JB. An Evaluation of the Role of Surveillance Imaging in Mantle Cell Lymphoma in First Remission. Blood (2016 ASH Annual Meeting) 128(22):1799, 2016.
55. Guidot, DM, Sethi, I, Switchenko, J, Lee, Daniel, Nastoupil, LJ, Koff, JL, Flowers, C, Cohen, JB. Use of Metabolic Tumor Volume (MTV) in Patients with Mantle Cell Lymphoma. Blood (2016 ASH Annual Meeting) 128(22):5321, 2016.
56. Chihara, D, Fanale, MA, Miranda, RN, Noorani, M, Westin, JR, Nastoupil, LJ, Hagemeister, FB, Fayad, LE, Romaguera, JE, Samaniego, F, Turturro, F, Lee, HJ, Neelapu, SS, Rodriguez, A, Wang, M, Fowler, N, Medeiros, LJ, Davis, RE, Oki, Y. The Risk of Central Nervous System (CNS) Relapses in Patients with Peripheral T-Cell Lymphoma. Blood (2016 ASH Annual Meeting) 128(22):4153, 2016.
57. Sathyanarayanan, V, Oki, Y, Issa, AK, Ahmed, MA, Noorani, M, Fanale, MA, Hagemeister, FB, Neelapu, SS, Nastoupil, LJ, Fowler, N, Turturro, F, Davis, RE, Rodriguez, A, Wang, M, Feng, L, Young, KH, McDonnell, TJ, Pinnix, CC, Fayad, LE, Westin, JR. High Risk Diffuse Large B Cell Lymphoma: A Comparison of Aggressive Subtypes Treated with Dose Adjusted Chemotherapy-the University of Texas MD Anderson Experience. Blood (2016 ASH Annual Meeting) 128(22):106, 2016.
58. Huang, S, Nastoupil, LJ, Guo, H, Bell, T, Ahmed, M, Li, CJ, Wang, J, Liu, Y, Zhang, V, Kim, CR, Boyle, JN, Lorence, EA, Lam, LT, Chen, Z, Zhang, H, Shuttleworth, SJ, Nomie, K, Wang, M, Zhang, L. Pre-Clinical Evaluation of the PI3K-p110β/δ Inhibitor KA2237 in Mantle Cell Lymphoma. Blood (2016 ASH Annual Meeting) 128(22):1837, 2016.
59. Young PA, Dang NH , Nastoupil LJ , Minning D, Gresser MJ , Timmerman L. Antibody-interferon-alpha Fusion Protein (IGN002) for the Treatment of B-cell Non-Hodgkin Lymphomas: A phase 1, first-in-Human, Dose-Escalation Trial. J Clin Oncol 34(15), 2016.
60. Khouri IF, Wang X, Turturro F, Jabbour E, Carballo-Zarate AA, Korbling M, Alousi AM, Oran B, Anderlini P, Ciurea SO, Patel KK, Marin D, Nastoupil LJ, Fanale MA, Samuels BI, Gulbis AM, Medeiros LJ, Khoury J. Long-term Outcomes of Non-myeloablative Allogeneic Stem Cell Transplantation (alloSCT) in Patients with Relapsed Mantle Cell Lymphoma (MCL). J Clin Oncol 34(15), 2016.
61. Issa A, Sathyanarayanan V, Fanale MA , Oki Y , Hagemeister FB, Neelapu SS, Nastoupil LJ, Fowler NH , Turturro F, Noorani M, Ahmed MA, Davis RE, Rodriguez MA, Wang M, Feng L, Young KH, McDonnell T, Pinnix CC, Fayad L, Westin JR. Outcomes of Diffuse Large B-cell Lymphoma with MYC and/or BCL2 Protein Expression Treated with Intensive Chemotherapy. J Clin Oncol 34(15), 2016.
62. Burris HA, Flinn I, Lunning MA, Vose J Fowler NH, Nastoupil LJ, O'Brien SM, Schreeder MT, Patel MR, Fenske T, Brander DM, Siddiqi T, Flowers C, Burger JA , Wierda WG, Kuhn JG, Sportelli P, Miskin HP, Weiss MS, O'Connor OA. Long-term Follow-up of the PI3Kδ Inhibitor TGR-1202 to Demonstrate a Differentiated Safety Profile and High Response Rates in CLL and NHL: Integrated-analysis of TGR-1202 Monotherapy and Combined with Ublituximab. J Clin Oncol 34(15), 2016.
63. Fowler N, Nastoupil L, Vos SD, Knapp M, Flinn IW, Chen RW, Advani RH, Bhatia S, Martin P, Mena R, Suzuki S, Beaupre DM, Neuenburg JK, Palomba ML. Ibrutinib Combined with Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Arm 1 + Arm 2 Results from a Multicenter, Open-Label Phase 2 Study. Blood 128(22):180, 2016.
64. Lee MJ, Switchenko J, Thomas J, Koff J, Nastoupil L, Lachowicz M, Langstrom A, Flowers C, Choen J. Complex Karyotype in Mantle Cell Lymphoma (MCL) is Associated with Inferior Progression-Free Survival in Patients (pts) Receiving R-Hypercvad Followed by Autologous Stem Cell Transplant. Blood (2015 ASH Annual Meeting) 126(23), 2015.
65. de Vos S, Swinnen L, Kazloff M, Wang D, Reid E, Nastoupil L, Fowler N, Cordero J, D'Amico D, Diehl S, Dunbar M, Zhu M, Wong S, Enschede S, Chien D, Humerickhouse R, Flowers C. A Dose-Escalation Study of Venetoclax (ABT-199/GDC-0199) in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma. Blood (2015 ASH Annual Meeting) 126(23), 2015.
66. Chihara D, Fanale M, Noorani M, Westin J, Nastoupil L, Hagemeister F, Fayad L, Romaguera J, Samaniego F, Turturro F, Lee HJ, Neelapu S, Rodriguez A, Wang M, Fowler N, Miranda R, Hosing C, Nieto Y, Davis RE, Oki Y. The Survival Outcome of the Patients with Relapsed/Refractory PTCL-NOS and AITL. Blood (2015 ASH Annual Meeting) 126(23), 2015.
67. Chihara D, Fanale M, Noorani M, Westin J, Nastoupil L, Hagemeister F, Fayad L, Romaguera J, Samaniego F, Turturro F, Le HJ, Neelapu S, Rodriguez A, Wang M, Fowler N, Miranda R, Hosing C, Nieto Y, Davis RE, Oki Y. The Survival Outcome of the Patients with Relapsed/Refractory Anaplastic Large-Cell Lymphoma. Blood (2015 ASH Annual Meeting) 126(123), 2015.
68. Chihara D, Oki Y, Westin J, Nastoupil L, Fayad L, Samaniego F, Wesson E, Roben C, Horowitz S, Feng L, Carg N, Ahmed S, Khouri I, Hosing C, Romaguera J, Fowler N, Fanale M. High Response Rate of Romidepsin in Combination with ICE(Ifosfamide, Carboplatin and Etoposide) in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma: Updates of Phase I Trial. Blood (2015 ASH Annual Meeting) 126(123), 2015.
69. Fowler N, Nastoupil L, de Vos S, Knapp M, Flinn I, Chen R, Advani R, Bhatia S, Martin P, Mena R, Suzuki S, Beaupre D, Neuenburg J, Palomba M. Ibrutinib Plus Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Results from a Multicenter Phase 2 Study. Blood (2015 ASH Annual Meeting) 126(123), 2015.
70. Ahmed M, Oki Y, Noorani M, Nastoupil L, Fayad L, Hagemeister F, Rodriguez A, Davis RE, Westin J. The Clinical Outcome of Newly Diagnosed Patients >60 Years of Age with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Standard or Liposomal Chemotherapies. Blood (2015 ASH Annual Meeting) 126(123), 2015.
71. Fowler N, Pinto R, Cheah C, Neelapu S, Turturro F, Hagemeister F, Romaguera J, Fanale M, Fayad L, Forbes S, Khan J, Feng L, Samaniego F, Nastoupil L. A Phase I Study of Lenalidomide Plus a Next Generation Anti-CD20 Antibody, Obinutuzumab, in Relapsed Indolent Lymphoma. Blood (2015 ASH Annual Meeting) 126(123), 2015.
72. Lunning M, Vose J, Fowler N, Nastoupil L, Burger J, Wierda W, Schreeder M, Siddiqi T, Flowers C, Cohen J, Blumel S, Migues M, Cutter K, Pauli E, Handy R, Sportelli P, Miskin H, Weiss M, O'Brien S. Ublituximab + TGR-1202 Demonstrates Activity and a Favorable Safety Profile in Relapsed/Refractory B-Cell NHL and High-Risk CLL: Phase I Results. Blood (2015 ASH Annual Meeting) 126(123), 2015.
73. Khouri I, Sui D, Turturro F, Erwin W, Bassett R, Korbling M, Valverde R, Ahmed S, Alousi A, Anderlini P, Bashire Q, Cuirea S, Oran B, Olson A, Popat U, Patel K, Qazilbash M, Fanale M, Fayad L, Nastoupil L, Westin J, Culbis A, Medeiros J, Young K, Jessop A. In-Vivo Purgine with Rituximab (r) Followed by Z/BEAM vs BEAM/R Autologous Stem Cell Conditioning for Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) Patients (pts): Mature Results from a Combined Analysis of 3 Trials. Blood (2015 ASH Annual Meeting) 126(123), 2015.
74. Chihara D, Ahmed M, Oki Y, Westin J, Hagemeister F, Romaguera J, Fanale M, Lee JH, Turturro F, Samaniego F, Neelapu S, Rodriguez A, Fowler, N, Wang M, Fayad L, Davis RE, Nastoupil L. Management Strategies and Outcomes for Very Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL). Blood (2015 ASH Annual Meeting) 126(123), 2015.
75. Mohamed AA, Fowler N, Ma L, Noorani M, Phansalkar K, Hagemeister FB, Romaguera JE, Fayad L, Rodriguez A, Samaniego F, Fanale M, Wan M, Oli Y, Turturro F, Westin J, Kwak L, Nastoupil L, Cheah C, Feng L, Rohren EM, David RE, Neelapu S. SUVmax on Pre-Treatment FDG PET Scan is Not Predictive of Outcome in Follicular Lymphoma after R-CHOP Therapy. Blood (ASH Annual Meeting 2014) 124(21), 2014.
76. Lunning MA, Vose JM, Schreeder MT, Fowler N, Nastoupil L, Siddiqu T, Blumel S, Paull EK, Cutter K, Tse W, Miskin HP, Sportelli P, Weiss MS, Vakkalanka S, Viswanadha S, O'Brien S. Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Combination with TGR-1202, a Next Generation Once Daily PI3k Inhibitor, Demonstrates Activity in Heavily Pre-Treated and High-Risk Chronic Lymphocytic Leukemia (CLL) and B-Cell Lymphoma. Blood (ASH Annual Meeting 2014) 124(21), 2014.
77. Rai A, Nastoupil L, Williams J, Lipscomb J, Ward K, Howard DH, Flowers C. Determinants and Outcomes of the Use of Positron Emission Tomography (PET)-Staging in Newly Diagnosed Follicular Lymphoma (FL). Blood (ASH Annual Meeting 2014) 124(21), 2014.
78. Williams J, rai A, Lipscomb J, Koff JL, Nastoupil L, Flowers CR. Disease Characteristics, Patterns of Care, and Survival in Very Elderly Patients with Diffuse Large B-Cell Lymphoma. Blood (ASH Annual Meeting 2014) 124(21), 2014.
79. Nastoupil L, Han X, Jemal A, Ward E, Flowers DR. Insurance Status Impacts Survival in Follicular Lymphoma. Blood (ASH Annual Meeting 2014) 124(21), 2014.
80. Phansalkar K, Ahmed MA, Fowler N, Ma Long, Noorani M, Lee ST, Feng L, Hagemeister FB, Romaguera JE, Fayad L, Rodriguez A, Samaniego F, Fanale M, Wang M, Oki Y, Turturro F, Westin J, Nastoupil L, Kwak L, David RE, Neelapu S. R-Bendamustine vs R-CHOP as Initial Treatment for Advanced Stage Low Grade Follicular Lymphoma: A Matched-Pair Analysis. Blood (ASH Annual Meeting 2014) 124(21), 2014.

Book Chapters

1. Nastoupil L. Molecular Targeting in Follicular Lymphoma. In: Management and current novel approaches, 2018.
2. Nastoupil L. Non-Hodgkin Lymphoma in adults Chapter 32. In: American Cancer Society's Oncology in Practice 2017, 2017.
3. Nastoupil L. Indolent Lymphoma. In: M.D. Anderson Manual of Medical Oncology. III. Cenveo Publisher Services, 133 - 152, 2016.